Page last updated: 2024-12-10

fisetin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5281614
CHEMBL ID31574
CHEBI ID42567
SCHEMBL ID39454
MeSH IDM0068970

Synonyms (136)

Synonym
BIDD:ER0141
unii-oo2abo9578
5-18-05-00291 (beilstein handbook reference)
oo2abo9578 ,
3,7,3',4'-tetrahydroxyflavone
DIVK1C_006556
KBIO1_001500
NCIMECH_000006
NCI60_003865
SDCCGMLS-0066657.P001
nsc-656275
inchi=1/c15h10o6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20
SPECTRUM_001196
nsc 656275
ccris 9034
bois bleude honqrie
nsc 407010
4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-
brn 0292829
flavone, 3,3',4',7-tetrahydroxy-
einecs 208-434-4
S00056
fisetin; 5-deoxyquercetin; 3,3?,4?,7-tetra??hydroxy??flavone; natural brown 1
NCGC00017344-01
tnp00004
NCGC00017344-02
bdbm7457
fisetin, 15
tnp00284 ,
chembl31574 ,
2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-chromone;dihydrate
2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-4h-chromen-4-one
NCGC00178374-01
SPECTRUM5_001797
5-desoxyquercetin
nsc656275
c.i. natural brown 1
3,7-dihydroxy-2-(3,4-dihydroxyphenyl)-4h-1-benzopyran-4-one
cotinin
c.i. 75620
2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-chromen-4-one
NSC407010 ,
3,3'4'7-tetoh-flavone
zante fustic
flavone,3',4',7-tetrahydroxy-
fustet
ventin sumach
superfustel
bois bleu de honqrie
fustel
fietin
young fustic crystals
4h-1-benzopyran-4-one,4-dihydroxyphenyl)-3,7-dihydroxy-
3,4',7-tetrahydroxyflavone
young fustic
junger fustik
superfustel k
ungarisches gelbholz
viset
nsc-407010
fisetholz
7,3',4'-trihydroxyflavonol
C10041
fisetin ,
528-48-3
CHEBI:42567 ,
3,3',4',7-tetrahydroxyflavone
2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-4h-1-benzopyran-4-one
1XO2
NCGC00095663-02
NCGC00095663-01
FSE ,
KBIO2_001676
KBIO2_004244
KBIOGR_001400
KBIO3_002452
KBIO2_006812
KBIOSS_001676
SPECPLUS_000460
SPECTRUM4_001070
SPECTRUM2_001160
SPBIO_001119
SPECTRUM3_001536
SPECTRUM1502247
BSPBIO_002952
fisidenolon 1521
AKOS000277885
DB07795
T0121
LMPK12111566
2-(3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one
A829279
CCG-35267
NCGC00017344-04
NCGC00017344-03
NCGC00017344-05
STL146392
natural brown 1
5-deoxyquercetin
fisetin hydrate
FT-0613996
NCGC00017344-06
S2298
gtpl5182
fisetin [mi]
fisetin [inci]
fisetin [who-dd]
BBL027612
SCHEMBL39454
MLS006011782
smr001835029
AC-34567
Q-100599
CS-7840
fisetine
2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-4h-chromen-4-one #
HMS3604H03
DTXSID4022317
HMS3655L22
SR-05000002249-2
sr-05000002249
SR-05000002249-3
J-019667
SW219914-1
HY-N0182
fisetin; 2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-4h-chromen-4-one
mfcd00006829
Q418384
fisetin(fustel)
fisetin (fustel)
AS-15520
4h-1-benzopyran-4-one,2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-
CS-0694983
HY-N0182R
fisetin (standard)
SY050263

Research Excerpts

Overview

Fisetin (FS) is a bioactive flavonoid obtained mostly from apple and strawberry. It is classified under the category of food supplements due to numerous pharmacological effects against various diseases through multiple mechanistic pathways.

ExcerptReferenceRelevance
"Fisetin is a polyphenolic flavonoid reported to have antioxidant, anti-inflammatory, and anti-cancer activities. "( Improved neuroprotective activity of Fisetin through SNEDDS in ameliorating the behavioral alterations produced in rotenone-induced Parkinson's model.
Awasthi, A; Dua, K; Khurana, N; Khurana, S; Khursheed, R; Kumar, R; Sharma, N; Singh, SK; Verma, S; Vishwas, S; Vyas, M, 2022
)
2.44
"Fisetin (FS) is a bioactive flavonoid obtained mostly from apple and strawberry and classified under the category of food supplements due to numerous pharmacological effects against various diseases through multiple mechanistic pathways. "( Harnessing the therapeutic potential of fisetin and its nanoparticles: Journey so far and road ahead.
Adams, J; Awasthi, A; Chellappan, DK; Collet, T; Corrie, L; Devkota, HP; Dua, K; Gulati, M; Gupta, G; Gupta, PK; Gupta, S; Jha, NK; Khursheed, R; Kumar, R; Loebenberg, R; Porwal, O; Singh, SK; Vishwas, S, 2022
)
2.43
"Fisetin is an effective flavonoid with antioxidant and anti-inflammatory properties, proven to be cardioprotective against IR injury in both in-vitro and invivo models, apart from its promising health benefits against cancer, diabetes, and neurodegenerative ailments."( Recent advances in potential of Fisetin in the management of myocardial ischemia-reperfusion injury-A systematic review.
Boovarahan, SR; Kurian, GA; Prem, PN; Sivakumar, B, 2022
)
1.73
"Fisetin, is a plant flavonol of the flavonoid family of plant polyphenols that has anticancer properties, partially through inhibition of p90 ribosomal S6 kinase (RSK)-mediated YB-1 phosphorylation."( Fisetin induces DNA double-strand break and interferes with the repair of radiation-induced damage to radiosensitize triple negative breast cancer cells.
Barletta, F; Distel, LV; Franz-Wachtel, M; Iliakis, G; Jost, T; Khozooei, S; Lettau, K; Macek, B; Rebholz, S; Toulany, M; Veerappan, S; Zips, D, 2022
)
2.89
"Fisetin acts as a DSB-inducing agent and simultaneously inhibits repair of IR-induced DSB. "( Fisetin induces DNA double-strand break and interferes with the repair of radiation-induced damage to radiosensitize triple negative breast cancer cells.
Barletta, F; Distel, LV; Franz-Wachtel, M; Iliakis, G; Jost, T; Khozooei, S; Lettau, K; Macek, B; Rebholz, S; Toulany, M; Veerappan, S; Zips, D, 2022
)
3.61
"Fisetin is a flavonoid molecule known to be neuroprotective by its multiple mechanisms. "( Fisetin provides neuroprotection in pentylenetetrazole-induced cognition impairment by upregulating CREB/BDNF.
Dahalia, M; Khatoon, S; Samim, M, 2023
)
3.8
"Fisetin (FIS) is a natural flavonoid with anti-proliferative and anti-apoptotic effects on different human cancer cell lines and can be considered a therapeutic agent for ALL treatment. "( Fisetin-loaded grape-derived nanoparticles improve anticancer efficacy in MOLT-4 cells.
Akbarzadelale, P; Gholipour, E; Khodadadi, M; Pourakbari, R; Samadi, P; Sarvarian, P; Shamsasenjan, K, 2023
)
3.8
"Fisetin (FST) is a dietary flavonol that is known to possess multiple relevant bioactivities, raising the question of its potential health benefits and even its use in novel pharmacological approaches against ER stress and inflammation."( Fisetin derivatives exhibit enhanced anti-inflammatory activity and modulation of endoplasmic reticulum stress.
Correia da Silva, D; Ferreira, PMT; Jervis, PJ; Martins, JA; Pereira, DM; Valentão, P, 2023
)
3.07
"Fisetin (FS) is an anticancer drug having potential role in oral tumors management. "( Fucoidan/hyaluronic acid cross-linked zein nanoparticles loaded with fisetin as a novel targeted nanotherapy for oral cancer.
Abdallah, OY; Awaad, AK; El-Mezayen, NS; El-Refaie, WM; Elnaggar, YSR; Moustafa, MA, 2023
)
2.59
"Fisetin (Fis) is a bioactive flavonoid that possesses strong bioactive activity."( Fisetin regulates the biological effects of rat nucleus pulposus mesenchymal stem cells under oxidative stress by sirtuin-1 pathway.
Ruan, D; Tang, L; Xuan, A; Zhang, J; Zhou, Q; Zhu, C; Zhu, Z, 2023
)
3.07
"Fisetin is a natural flavonoid with anti-inflammatory and antiallergic pharmacological effects."( Fisetin alleviates chronic urticaria by inhibiting mast cell activation via MRGPRX2.
Dang, B; Hu, S; Huang, Y; Liu, R; Wang, Y; Yuan, Y; Zhang, Y; Zhao, C, 2023
)
3.07
"Fisetin (FST) is a naturally occurring flavonol that has recently emerged as a bioactive phytochemical with an impressive array of biological activities. "( Formulation of lipid polymer hybrid nanoparticles of the phytochemical Fisetin and its in vivo assessment against severe acute pancreatitis.
Abu Hashim, II; Awadeen, RH; Boughdady, MF; Elsaed, WM; Meshali, MM; Zaghloul, RA, 2023
)
2.59
"Fisetin is a dietary flavonoid that has shown forceful anti-inflammatory and anti-proliferative properties in diverse models of disease."( Fisetin Alleviates Atrial Inflammation, Remodeling, and Vulnerability to Atrial Fibrillation after Myocardial Infarction.
Gan, S; Ge, X; Li, B; Liu, L; Yu, H; Zhou, H, 2019
)
2.68
"Fisetin (FS) is a polyphenolic phytoconstituent reported to have various pharmacological activities such as antioxidant, antiparkinsonian, and antidepressant. "( Validated Reverse Phase-High-Performance Liquid Chromatography Method for Estimation of Fisetin in Self-Nanoemulsifying Drug Delivery System.
Awasthi, A; Kapoor, B; Kaur, J; Khurana, N; Khurana, S; Khursheed, R; Kumar, R; Pandey, NK; Ramanunny, AK; Sharma, N; Singh, SK,
)
1.8
"Fisetin is a natural flavonoid that shows diverse antitumor effects, including DNA damage, in various cancers."( Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation.
Cao, L; Chen, Y; Ding, G; Jia, S; Li, D; Ping, D; Wang, W; Xu, X, 2020
)
2.72
"Fisetin is a bioactive flavonol that inhibits osteoclastogenesis and promotes osteoblastogenesis. "( Fisetin promotes osteoblast differentiation and osteogenesis through GSK-3β phosphorylation at Ser9 and consequent β-catenin activation, inhibiting osteoporosis.
Choi, YH; Kang, CH; Kim, GY; Lee, CM; Lee, MH; Lee, S; Molagoda, IMN, 2021
)
3.51
"Fisetin is a natural compound found in fruits and vegetables such as strawberries, apples, cucumbers, and onions. "( Fisetin Induces Apoptosis Through p53-Mediated Up-Regulation of DR5 Expression in Human Renal Carcinoma Caki Cells.
Kwon, TK; Min, KJ; Nam, JO, 2017
)
3.34
"Fisetin is a naturally occurring flavonoid in strawberries that has anti-inflammatory activities, but whether fisetin has antidepressant effects is unknown."( Fisetin provides antidepressant effects by activating the tropomyosin receptor kinase B signal pathway in mice.
Chua, BHL; Gong, S; Hamdy, RC; Lu, J; Shi, H; Wang, B; Wang, Y; Xu, X; Yang, L, 2017
)
2.62
"Fisetin is a polyphenolic molecule of flavonoids class, and belongs to the bioactive phytochemicals that have potential to block multiple signaling pathways associated with NCDs such as cell division, angiogenesis, metastasis, oxidative stress, and inflammation."( Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy.
Bishayee, A; Buttar, HS; Kashyap, D; Sak, K; Sharma, A; Tuli, HS, 2018
)
2.64
"Fisetin is a naturally occurring compound that has been reported to have antitumor effects, but its effects on epidermal growth factor (EGF)-induced cell migration and the underlying mechanisms remain unclear."( Fisetin inhibits epidermal growth factor-induced migration of ARPE-19 cells by suppression of AKT activation and Sp1-dependent MMP-9 expression.
Chen, YS; Chien, HW; Hsieh, YH; Lin, HY; Wang, K; Yang, SF, 2017
)
2.62
"Fisetin is a flavonol compound commonly found in edible vegetables and fruits. "( Selective inhibition of CYP2C8 by fisetin and its methylated metabolite, geraldol, in human liver microsomes.
Kim, JH; Lee, HS; Lee, JM; Lee, S; Nam, W; Shrestha, R, 2018
)
2.2
"Fisetin is a naturally abundant flavonoid isolated from various fruits and vegetables that was recently identified to have potential biological functions in improving allergic airway inflammation, as well as anti-oxidative and anti-tumor properties. "( Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Chen, YL; Cheng, CY; Huang, WC; Liou, CJ; Wang, CL; Wei, CH, 2018
)
3.37
"Fisetin is a plant flavonoid reported to have anti-inflammatory and antiapoptotic potential."( Fisetin, a plant flavonoid ameliorates doxorubicin-induced cardiotoxicity in experimental rats: the decisive role of caspase-3, COX-II, cTn-I, iNOs and TNF-α.
Bodhankar, SL; Kandhare, AD; Ma, T; Mukherjee-Kandhare, AA, 2019
)
2.68
"Fisetin is a natural flavonoid with promising antitumor activity, whereas its clinical application is limited by its hydrophobic property. "( Preparation and optimization of poly (lactic acid) nanoparticles loaded with fisetin to improve anti-cancer therapy.
Chu, K; Feng, C; Ji, W; Rui, M; Yuan, X; Zhang, H, 2019
)
2.19
"Fisetin is a bioactive flavonol molecule found in many plants and possesses various biological activities."( Fisetin ameliorates oxidative stress, inflammation and apoptosis in diabetic cardiomyopathy.
Abukhalil, MH; Al Hroob, AM; Althunibat, OY; Bin-Jumah, M; Germoush, MO; Mahmoud, AM, 2019
)
2.68
"Fisetin (Fn) is a bioactive flavonoid polyphenol with anti-inflammatory and anti-tumor activity."( Activated TNF-α/RIPK3 signaling is involved in prolonged high fat diet-stimulated hepatic inflammation and lipid accumulation: inhibition by dietary fisetin intervention.
Ge, C; Gu, T; Hu, L; Huang, P; Li, Q; Lou, D; Lv, J; Ma, Y; Nie, X; Qin, Y; Tan, J; Wang, M; Wang, S; Xu, M, 2019
)
1.43
"Fisetin (FST) is a phenolic compound that has been isolated from many natural products."( Protective effect of 7,3',4'-flavon-3-ol (fisetin) on acetaminophen-induced hepatotoxicity in vitro and in vivo.
Chen, L; Hu, C; Jia, Y; Liu, X; Pan, L; Wang, Y; You, L; Zhang, J; Zhao, L, 2019
)
1.5
"Fisetin is a flavonol found in fruits and vegetables and is reported to inhibit cell growth in numerous cancers."( Fisetin activates Hippo pathway and JNK/ERK/AP-1 signaling to inhibit proliferation and induce apoptosis of human osteosarcoma cells via ZAK overexpression.
Chen, MC; Fu, CY; Huang, CY; Lin, YM; Tseng, YS; Viswanadha, VP; Wang, G; Yang, JJ; Zhou, Z, 2019
)
2.68
"Fisetin is a small, orally active molecule which can act on many of the target pathways implicated in AD."( Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic mice.
Armando, A; Currais, A; Dargusch, R; Ehren, J; Maher, P; Prior, M; Quehenberger, O; Schubert, D, 2014
)
1.38
"Fisetin is a bio-flavonoid widely found in plants and exerts antitumor activity in several types of human cancers."( Melatonin enhances the anti-tumor effect of fisetin by inhibiting COX-2/iNOS and NF-κB/p300 signaling pathways.
Deng, W; Guo, W; Qiu, H; Tang, R; Wang, J; Xiao, Y; Yi, C; Yu, W; Yu, Z; Yuan, Y; Zhang, Y, 2014
)
1.38
"Fisetin is a bioactive flavonoid with recognized antioxidant and anti-inflammatory properties."( Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-κB activation and antioxidant defence.
Kalvala, AK; Koneru, M; Kuncha, M; Mahesh Kumar, J; Rachamalla, SS; Sahu, BD; Sistla, R, 2014
)
1.43
"Fisetin is an anti-inflammatory flavonoid; however, its anti-inflammatory mechanism is not yet understood. "( Anti-inflammatory activity of fisetin in human gingival fibroblasts treated with lipopolysaccharide.
Contreras-Sánchez, A; Gutiérrez-Venegas, G; Ventura-Arroyo, JA, 2014
)
2.13
"Fisetin is an effective compound extracted from lacquer which has been used in the treatment of various diseases. "( Interference of fisetin with targets of the nuclear factor-κB signal transduction pathway activated by Epstein-Barr virus encoded latent membrane protein 1.
Li, MY; Li, R; Liang, HY; Lin, CY; Shi, MJ; Zhang, XJ, 2014
)
2.19
"Fisetin is a naturally occurring flavonoid abundantly found in several vegetables and fruits."( Fisetin inhibits TNF-α-induced inflammatory action and hydrogen peroxide-induced oxidative damage in human keratinocyte HaCaT cells through PI3K/AKT/Nrf-2-mediated heme oxygenase-1 expression.
Jeong, GS; Seo, SH, 2015
)
2.58
"Fisetin is a well known flavonoid that shows several properties such as antioxidant, antiviral and anticancer activities. "( Preparation of albumin based nanoparticles for delivery of fisetin and evaluation of its cytotoxic activity.
Chaudhury, K; Chaudhury, S; Dasgupta, S; Ghosh, P; Jana, SK; Singha Roy, A, 2016
)
2.12
"Fisetin is a compound that acts in the biosynthesis of ergosterol. "( Fisetin as a promising antifungal agent against Cryptocococcus neoformans species complex.
Andrade, FA; Arruda, W; Carvalho, CR; Fernandes, OF; Reis, MP; Silva, MR, 2016
)
3.32
"Fisetin is a naturally occurring flavonoid commonly found in various vegetables and fruits."( A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways.
Afaq, F; Johnson, JJ; Mukhtar, H; Suh, Y, 2009
)
1.41
"Fisetin is a natural flavonol present in edible vegetables, fruits and wine at 2-160 microg/g concentrations and an ingredient in nutritional supplements with much higher concentrations. "( Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint.
Gorbsky, GJ; Halonen, PK; Kallio, MJ; Kallioniemi, O; Kukkonen, AM; Perälä, M; Pouwels, J; Salmela, AL; Toivonen, P; Varis, A, 2009
)
2.13
"Fisetin is a flavonoid dietary ingredient found in the smoke tree (Cotinus coggyria) and in several fruits and vegetables. "( The actions of fisetin on glucose metabolism in the rat liver.
Bracht, A; Constantin, J; Constantin, RP; Ishii-Iwamoto, EL; Ono, Mde K; Pagadigorria, CL; Yamamoto, NS, 2010
)
2.16
"Fisetin is a natural flavonoid from fruits and vegetables that exhibits antioxidant, neurotrophic, anti-inflammatory, and anti-cancer effects in various disease models. "( Fisetin induces Nrf2-mediated HO-1 expression through PKC-δ and p38 in human umbilical vein endothelial cells.
Jeong, SI; Jin, YH; Lee, SE; Park, CS; Park, YS; Yang, H, 2011
)
3.25
"Fisetin is a naturally occurring flavonoid that has been reported to inhibit the proliferation and to induce apoptotic cell death in several tumor cells. "( Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-mediated activation of caspase-8-/caspase-3-dependent pathway.
Bau, DT; Hsieh, SC; Hsieh, YH; Huang, YC; Tsai, SJ; Yang, SF; Ying, TH, 2012
)
3.26
"Fisetin was confirmed to be an effective topo II inhibitor."( Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin.
Eastmond, DA; Mondrala, ST; Olaharski, AJ, 2005
)
1.27

Effects

Fisetin has been reported to have various positive biological effects, including anti-proliferative, anticancer, anti-oxidative and neuroprotective effects. The flavonoid has affinity on some neuronal targets and may have the potential to modulate neuronal activity.

ExcerptReferenceRelevance
"Fisetin has direct antioxidant activity and can also increase the intracellular levels of glutathione (GSH), the major endogenous antioxidant."( Chemical modification of the multitarget neuroprotective compound fisetin.
Chiruta, C; Dargusch, R; Maher, P; Schubert, D, 2012
)
1.34
"Fisetin has manifested several health benefits in preclinical models of neurodegenerative diseases such as Alzheimer's disease, Vascular dementia, and Schizophrenia."( Fisetin, potential flavonoid with multifarious targets for treating neurological disorders: An updated review.
Boyina, HK; Kalakotla, S; Pasangulapati, JP; Perumal, V; Ravula, AR; Teegala, SB, 2021
)
2.79
"Fisetin has affinity on some neuronal targets and may have the potential to modulate neuronal activity."( Fisetin decreases the duration of ictal-like discharges in mouse hippocampal slices.
Abidin, I; Aydin-Abidin, S; Basoglu, H; Ozturk, H; Yorulmaz, N, 2022
)
2.89
"Fisetin has been shown to confer protection against liver injury."( Fisetin Ameliorates Alcohol-Induced Liver Injury through Regulating SIRT1 and SphK1 Pathway.
Kong, CF; Qu, XK; Sun, AT; Sun, JH; Sun, JR; Zhou, ZS, 2022
)
2.89
"Fisetin has wide pharmacological effects such as anticancer, antiinflammatory and antioxidant."( Fisetin Attenuates Paracetamol-Induced Hepatotoxicity by Regulating CYP2E1 Enzyme.
Cadirci, E; Cinar, I; Gurbuz, MA; Ugan, RA; Un, H, 2023
)
3.07
"Fisetin also has anti-oxidant, anti-inflammatory, and anti-tumor effects."( Fisetin, an Anti-Inflammatory Agent, Overcomes Radioresistance by Activating the PERK-ATF4-CHOP Axis in Liver Cancer.
Kim, TW, 2023
)
3.07
"Fisetin, a flavonoid, has emerged as a novel potential molecule that enhances neural protection and reverses cognitive abnormalities."( The Neuroprotective Role of Fisetin in Different Neurological Diseases: a Systematic Review.
Deng, P; Hao, D; He, Y; Jiang, C; Jiang, Y; Tang, X; Yang, H, 2023
)
1.93
"Fisetin has various biological effects including anti-inflammatory, antioxidant, apoptotic, and antiproliferative activities."( Evaluation of the anti-inflammatory activity of fisetin-loaded nanoparticles in an in vitro model of osteoarthritis.
Mirmohammadkhani, M; Nabizadeh, Z; Nasrabadi, D; Nasrollahzadeh, M; Shabani, AA, 2023
)
1.89
"Fisetin has anti-inflammatory, anti-aging and anti-oxidative properties."( Fisetin mitigates hepatic ischemia-reperfusion injury by regulating GSK3β/AMPK/NLRP3 inflammasome pathway.
Huang, ZT; Li, TT; Li, ZT; Luo, YH; Mou, T; Pu, JL; Wei, XF; Wu, ZJ, 2021
)
2.79
"Fisetin has also been shown to inhibit the metastatic spread of cancer cells in tumor-bearing mice."( Cancer chemopreventive role of fisetin: Regulation of cell signaling pathways in different cancers.
Attar, R; Farooqi, AA; Naureen, H; Xu, B; Youssef, L; Zahid, R, 2021
)
1.63
"Fisetin has been reported to have various positive biological effects, including anti-proliferative, anticancer, anti-oxidative and neuroprotective effects."( Carnosic acid and fisetin combination therapy enhances inhibition of lung cancer through apoptosis induction.
Chen, L; Meng, WS; Meng, ZL; Shi, B; Wang, LF, 2017
)
1.51
"Fisetin has been reported to relate to various positive biological effects, including anti-proliferative, anticancer, anti-oxidative and neuroprotective effects."( Fisetin inhibits liver cancer growth in a mouse model: Relation to dopamine receptor.
Liu, GL; Liu, XF; Long, HJ; Miao, XY; Yao, HL, 2017
)
2.62
"Fisetin has been identified as an anticancer agent with antiangiogenic properties in mice. "( UHPLC-Q-TOF-MS/MS Method Based on Four-Step Strategy for Metabolism Study of Fisetin in Vitro and in Vivo.
Liang, C; Sun, Y; Yin, J; Zhang, L; Zhang, X, 2017
)
2.13
"Fisetin has been reported to exhibit various positive biological effects, including anti-proliferative, anticancer, anti-oxidative and neuroprotective effects."( Fisetin-treatment alleviates airway inflammation through inhbition of MyD88/NF-κB signaling pathway.
Huang, W; Li, ML; Shao, JY; Xia, MY, 2018
)
2.64
"Fisetin has also been demonstrated to have anti-obesity properties in mice."( Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Chen, YL; Cheng, CY; Huang, WC; Liou, CJ; Wang, CL; Wei, CH, 2018
)
2.64
"Fisetin has various physiological effects that include anti-oxidation, anti-angiogenesis, anti-carcinogenesis and anti-inflammation."( Immunosuppressive effects of fisetin against dinitrofluorobenzene-induced atopic dermatitis-like symptoms in NC/Nga mice.
Kim, GD; Lee, SE; Park, CS; Park, GG; Park, YS; Shin, DH, 2014
)
1.41
"Fisetin not only has direct antioxidant activity but it can also increase the intracellular levels of glutathione, the major intracellular antioxidant."( How fisetin reduces the impact of age and disease on CNS function.
Maher, P, 2015
)
1.7
"Fisetin not only has direct antioxidant activity but it can also increase the intracellular levels of glutathione, the major intracellular antioxidant."( Cell and brain tissue imaging of the flavonoid fisetin using label-free two-photon microscopy.
Ehren, J; Krasieva, TB; Maher, P; O'Sullivan, T; Tromberg, BJ, 2015
)
1.4
"Fisetin has been shown to exert various positive biological effects, such as anti-cancer, anti-proliferative, neuroprotective and anti-oxidative effects."( Fisetin inhibits TNF-α-induced inflammatory action and hydrogen peroxide-induced oxidative damage in human keratinocyte HaCaT cells through PI3K/AKT/Nrf-2-mediated heme oxygenase-1 expression.
Jeong, GS; Seo, SH, 2015
)
2.58
"Fisetin has been shown to inhibit or retard the growth of various cancer cells in culture and implanted tumors in vivo."( The flavonoid fisetin as an anticancer agent targeting the growth signaling pathways.
Rengarajan, T; Yaacob, NS, 2016
)
1.52
"Fisetin, a flavonoid, has multiple biological effects, including neuroprotective and antiinflammatory properties."( The flavonoid fisetin attenuates postischemic immune cell infiltration, activation and infarct size after transient cerebral middle artery occlusion in mice.
Arumugam, TV; Birkenmayer, G; Gelderblom, M; Gerloff, C; Lewerenz, J; Leypoldt, F; Ludewig, P; Magnus, T; Maher, P; Orozco, D; Thundyil, J; Tolosa, E, 2012
)
1.46

Actions

Fisetin was found to inhibit survival of CCA cells, through strongly phosphorylating ERK. The survival-promoting effect of fiset in was also not dependent on glutathione. F isetin plays a senolytic role by specifically eliminating senescent cells, inhibiting cell proliferation and exerting anti-inflammatory, anti-oxidant, and anti-tumorigenic effects.

ExcerptReferenceRelevance
"Fisetin plays a senolytic role by specifically eliminating senescent cells, inhibiting cell proliferation, and exerting anti-inflammatory, anti-oxidant, and anti-tumorigenic effects."( Fisetin reduces the senescent tubular epithelial cell burden and also inhibits proliferative fibroblasts in murine lupus nephritis.
Chikenji, TS; Ijima, S; Iwamoto, T; Miura, N; Miyajima, M; Nagaoka, K; Saito, Y; Sato, T; Yamamoto, S, 2022
)
2.89
"Fisetin showed lower toxicity (IC50 = 158 μg/mL) than the fresh xylem sap (IC50 = 109 μg/mL)."( Antifungal and cytotoxicity activities of the fresh xylem sap of Hymenaea courbaril L. and its major constituent fisetin.
Alves de Oliveira, CM; Andrade, WM; Bozinis, MC; Costa, CR; da Costa, MP; da Silva, AL; Fernandes, Ode F; Kato, L; Silva, Mdo R; Souza, LK, 2014
)
1.33
"Fisetin can also activate key neurotrophic factor signaling pathways."( How fisetin reduces the impact of age and disease on CNS function.
Maher, P, 2015
)
1.7
"Fisetin can also activate key neurotrophic factor signaling pathways."( Cell and brain tissue imaging of the flavonoid fisetin using label-free two-photon microscopy.
Ehren, J; Krasieva, TB; Maher, P; O'Sullivan, T; Tromberg, BJ, 2015
)
1.4
"Fisetin could inhibit major Ca(2+) mobilization pathways including extracellular Ca(2+) influx mediated by the L-type voltage-gated Ca(2+) channel, Ca(2+) release from the intracellular store and store-operated Ca(2+) entry."( Heartwood extract of Rhus verniciflua Stokes and its active constituent fisetin attenuate vasoconstriction through calcium-dependent mechanism in rat aorta.
Lee, D; Lee, JH; Lee, JY; Lee, MY; Na, CS; Park, JM; Satoh, M, 2016
)
1.39
"Fisetin was found to inhibit survival of CCA cells, through strongly phosphorylating ERK. "( Fisetin Reduces Cell Viability Through Up-Regulation of Phosphorylation of ERK1/2 in Cholangiocarcinoma Cells.
Kang, MJ; Kim, BH; Kim, N; Kim, YT; Lee, JM; Lee, JS; Lee, SH; Ryu, JK; Son, JH, 2016
)
3.32
"Fisetin can enhance glutathione synthesis but the survival-promoting effect of fisetin was also not dependent on glutathione."( The flavonoid fisetin promotes nerve cell survival from trophic factor withdrawal by enhancement of proteasome activity.
Maher, P, 2008
)
1.43

Treatment

Fisetin treatment reduced expression of the key initiators of allergic airway inflammation (eotaxin-1 and TSLP), Th2-associated cytokines (IL-4, IL-5, and IL-13) in lungs. FisetIn treatment also resulted in induction of apoptosis, poly (ADP-ribose) polymerase (PARP) cleavage, modulation in the expressions of Bcl-2 family proteins.

ExcerptReferenceRelevance
"Fisetin pretreatment attenuates renal IR injury by improving renal function, reducing the renal injury mediated by apoptosis, reducing free radical release, and augmenting mitochondrial function."( Fisetin attenuates renal ischemia/reperfusion injury by improving mitochondrial quality, reducing apoptosis and oxidative stress.
Kurian, GA; Prem, PN, 2022
)
2.89
"Fisetin treatment reduced endometriotic implant area, diameter, and volumes, as well as histological alterations, neutrophil infiltration, cytokines release, the number of MCs together with the expression of chymase and tryptase, and diminished α smooth muscle actin (α-sma) and transforming growth factor beta (TGF β) expressions."( Fisetin, a Natural Polyphenol, Ameliorates Endometriosis Modulating Mast Cells Derived NLRP-3 Inflammasome Pathway and Oxidative Stress.
Arangia, A; Cordaro, M; Cuzzocrea, S; D'Amico, R; Di Paola, R; Fusco, R; Impellizzeri, D; Macrì, F; Marino, Y; Raffone, E; Siracusa, R, 2023
)
3.07
"Fisetin treated male mice had reduced SASP, enhanced glucose and energy metabolism, improved cognitive performance, and increased mRNA expression of adiponectin receptor 1 and glucose transporter 4."( Sexual dimorphic metabolic and cognitive responses of C57BL/6 mice to Fisetin or Dasatinib and quercetin cocktail oral treatment.
Bartke, A; Fang, Y; Hascup, ER; Hascup, KN; McFadden, S; Medina, D; Peck, MR; Quinn, K; Stockwell, R, 2023
)
1.87
"The fisetin-treated cells showed increased ROS level and a significant decline in nuclear Nrf2 immunosignal versus recovery in nuclear Nrf2 due to the treatment with curcumin and resveratrol (Nrf2 activators) and thus, suggesting a role of Nrf2 suppression in fisetin-mediated apoptosis in SW-480 cells."( Fisetin induces apoptosis in colorectal cancer cells by suppressing autophagy and down-regulating nuclear factor erythroid 2-related factor 2 (Nrf2).
Pandey, A; Trigun, SK, 2023
)
2.83
"Fisetin treatment significantly inhibited proliferation and promoted apoptosis by repressing PAK4 expression. "( Fisetin Modulates Human Oral Squamous Cell Carcinoma Proliferation by Blocking PAK4 Signaling Pathways.
Dai, W; Jia, S; Li, Y, 2020
)
3.44
"Fisetin treatment increased reactive oxygen species (ROS) from 100 in untreated to 220% at 36 µM and decreased mitochondrial membrane potential (MMP) levels from 100 in untreated to 21% at 36 µM."( Anticancer activity of Fisetin against the human osteosarcoma cell lines involves G2/M cell cycle arrest, mitochondrial apoptosis and inhibition of cell migration and invasion.
Su, R; Wu, R; Xing, C; Zhang, Y,
)
1.16
"Fisetin pretreatment upregulated the expression of PPAR-γ in heart tissue significantly Cardioprotection was assessed by measurement of hemodynamic parameters, infarct size, ELISA for oxidative stress, immunohistochemistry and TUNEL assay for apoptosis, and western blot analysis for MAPK proteins and inflammation."( The molecular mechanism involved in cardioprotection by the dietary flavonoid fisetin as an agonist of PPAR-γ in a murine model of myocardial infarction.
Arya, DS; Bhatia, J; Garg, S; Kaur, P; Khan, SI; Kumar, M; Malhotra, RK; Nag, TC; Sharma, MK, 2020
)
1.51
"In fisetin-treated animals, pro-inflammatory cytokine release was downregulated accompanied with TLR4/NF-κB inactivation."( Fisetin administration improves LPS-induced acute otitis media in mouse in vivo.
Chen, D; Huang, Y; Li, P, 2018
)
2.44
"Fisetin treatment lowered these parameters, suggesting the alleviation of brain injury."( Fisetin Protects against Intracerebral Hemorrhage-Induced Neuroinflammation in Aged Mice.
Chen, C; Cui, J; Liu, B; Yao, L, 2018
)
2.64
"Fisetin treatment also reduced liver lipid droplet and hepatocyte steatosis, alleviated serum free fatty acid, and leptin concentrations, significantly decreased fatty acid synthase, and significantly increased phosphorylation of AMPKα and the production of sirt-1 and carnitine palmitoyltransferase I in the liver tissue."( Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Chen, YL; Cheng, CY; Huang, WC; Liou, CJ; Wang, CL; Wei, CH, 2018
)
2.64
"Fisetin treatment of preadipocytes reduced the phosphorylation of S6K1 and mTORC1 in a time- and concentration-dependent manner."( Fisetin regulates obesity by targeting mTORC1 signaling.
Ahn, J; Ha, TY; Jeon, TI; Jung, CH; Kim, H; Lee, DH, 2013
)
2.55
"Fisetin treatment of A431 cells resulted in G₂ /M arrest and induction of apoptosis."( Fisetin inhibits growth, induces G₂ /M arrest and apoptosis of human epidermoid carcinoma A431 cells: role of mitochondrial membrane potential disruption and consequent caspases activation.
Afaq, F; Athar, M; Elmets, CA; Pal, HC; Sharma, S, 2013
)
2.55
"Upon fisetin treatment to diabetic rats, the levels of blood glucose were significantly reduced with an improvement in plasma insulin."( Antihyperlipidemic effect of fisetin, a bioflavonoid of strawberries, studied in streptozotocin-induced diabetic rats.
Prasath, GS; Subramanian, SP, 2014
)
1.15
"Fisetin treatment induced endoplasmic reticulum (ER) stress in highly aggressive A375 and 451Lu human melanoma cells, as revealed by up-regulation of ER stress markers including IRE1α, XBP1s, ATF4 and GRP78."( Involvement of ER stress and activation of apoptotic pathways in fisetin induced cytotoxicity in human melanoma.
Chamcheu, JC; Haidar, O; Lall, RK; Mukhtar, H; Syed, DN, 2014
)
1.36
"Fisetin treatment to UVB-exposed mice resulted in decreased hyperplasia and reduced infiltration of inflammatory cells."( Fisetin inhibits UVB-induced cutaneous inflammation and activation of PI3K/AKT/NFκB signaling pathways in SKH-1 hairless mice.
Afaq, F; Athar, M; Elmets, CA; Pal, HC,
)
2.3
"Fisetin treatment also significantly attenuated the cisplatin-induced IκBα degradation and phosphorylation and blocked the NF-κB (p65) nuclear translocation, with subsequent elevation of pro-inflammatory cytokine, TNF-α, protein expression of iNOS and myeloperoxidase activities."( Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-κB activation and antioxidant defence.
Kalvala, AK; Koneru, M; Kuncha, M; Mahesh Kumar, J; Rachamalla, SS; Sahu, BD; Sistla, R, 2014
)
1.43
"Fisetin treatment of human prostate cancer cells resulted in robust up-regulation of microtubule associated proteins (MAP)-2 and -4."( Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells.
Adhami, VM; Mukhtar, E; Mukhtar, H; Sechi, M, 2015
)
1.47
"Fisetin treatment reduced the interleukin-6 and tumour necrosis factor-alpha in sciatic nerves of diabetic rats (p < 0.001)."( Fisetin Imparts Neuroprotection in Experimental Diabetic Neuropathy by Modulating Nrf2 and NF-κB Pathways.
Areti, A; Komirishetti, P; Kumar, A; Sandireddy, R; Yerra, VG, 2016
)
2.6
"Fisetin treatment to DSS-exposed mice significantly reduced the severity of colitis and alleviated the macroscopic and microscopic signs of the disease."( Fisetin, a dietary flavonoid, ameliorates experimental colitis in mice: Relevance of NF-κB signaling.
Kumar, JM; Sahu, BD; Sistla, R, 2016
)
2.6
"Fisetin pretreatment (20 mg/kg body wt., p.o.) of rats for 12 weeks were chosen followed by injecting iron (5 µl, 100 mM) stereotaxically to generate iron-induced epilepsy. "( Antiepileptic effect of fisetin in iron-induced experimental model of traumatic epilepsy in rats in the light of electrophysiological, biochemical, and behavioral observations.
Das, J; Sharma, D; Singh, R, 2017
)
2.2
"Fisetin pretreatment was found to prevent the development of iron-induced electrical seizure and decrease the corresponding MUA in the cortex (*P˂0.05) as well as in the hippocampus (***P˂0.001). "( Antiepileptic effect of fisetin in iron-induced experimental model of traumatic epilepsy in rats in the light of electrophysiological, biochemical, and behavioral observations.
Das, J; Sharma, D; Singh, R, 2017
)
2.2
"Fisetin treatment downregulated intracellular and secreted HA levels both in vitro and in vivo Fisetin inhibited HA synthesis and degradation enzymes, which led to cessation of HA synthesis and also repressed the degradation of the available high-molecular-mass (HMM)-HA."( Dietary flavonoid fisetin increases abundance of high-molecular-mass hyaluronan conferring resistance to prostate oncogenesis.
Adhami, VM; Gong, Y; Khan, MI; Lall, RK; Lucey, JA; Mukhtar, H; Syed, DN, 2016
)
1.49
"Fisetin treatment of cells also inhibited the activation of EGFR and nuclear factor-kappa B (NF-kappaB)."( A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways.
Afaq, F; Johnson, JJ; Mukhtar, H; Suh, Y, 2009
)
1.41
"Fisetin treatment resulted in dose-dependent inhibition of PaC cell growth and cell proliferation with concomitant induction of apoptosis."( Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB.
Adhami, VM; Hafeez, BB; Mukhtar, H; Murtaza, I; Saleem, M, 2009
)
2.52
"Fisetin pretreatment enhanced the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells but not human keratocyte HaCaT cells; it also prolonged radiation-induced G(2)/M arrest, enhanced radiation-induced cell growth arrest in HT-29 cells, and suppressed radiation-induced phospho-H2AX (Ser-139) and phospho-Chk2 (Thr-68) in p53-mutant HT-29 cells. "( Enhancement of p53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetin.
Chen, WS; Chiu, SJ; Hsaio, CH; Lee, YJ; Tsai, YJ; Yen, JH; Yu, SH; Yu, YC, 2010
)
2.03
"Fisetin treatment significantly attenuated migration of dendritic cells into spleens and dendritic cell-mediated T cell activation in LPS-treated mice."( Fisetin inhibits lipopolysaccharide-induced macrophage activation and dendritic cell maturation.
Chi, CW; Chou, JH; Fu, SL; Hung, SK; Lin, CH; Liu, SH, 2010
)
2.52
"Fisetin-treated cells showed increased cytosolic levels of Axin and β-TrCP and decreased phosphorylation of glycogen synthase kinase 3β associated with decreased β-catenin stabilization."( Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/β-catenin signaling and decreased Mitf levels.
Afaq, F; Ahmad, A; Johnson, JJ; Maddodi, N; Mukhtar, H; Sarfaraz, S; Setaluri, V; Syed, DN, 2011
)
1.33
"Fisetin treatment resulted in significantly increased NF-E2-related factor 2 (Nrf2) nuclear translocation, and antioxidant response element (ARE)-luciferase activity, leading to up-regulation of HO-1 expression."( Fisetin induces Nrf2-mediated HO-1 expression through PKC-δ and p38 in human umbilical vein endothelial cells.
Jeong, SI; Jin, YH; Lee, SE; Park, CS; Park, YS; Yang, H, 2011
)
2.53
"Fisetin treatment was also found to reduce the formation of A549 cell colonies in a dose-dependent manner."( Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.
Afaq, F; Khan, N; Khusro, FH; Mukhtar, H; Mustafa Adhami, V; Suh, Y, 2012
)
1.3
"Fisetin treatment reduced expression of the key initiators of allergic airway inflammation (eotaxin-1 and TSLP), Th2-associated cytokines (IL-4, IL-5, and IL-13) in lungs, and Th2-predominant transcription factor GATA-3 and cytokines in thoracic lymph node cells and splenocytes."( Immunosuppressive effects of fisetin in ovalbumin-induced asthma through inhibition of NF-κB activity.
Fu, SL; Hung, SK; Wu, MY, 2011
)
1.38
"Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin."( Fisetin averts oxidative stress in pancreatic tissues of streptozotocin-induced diabetic rats.
Prasath, GS; Subramanian, SP; Sundaram, CS, 2013
)
2.55
"Fisetin treatment also resulted in induction of apoptosis, poly (ADP-ribose) polymerase (PARP) cleavage, modulation in the expressions of Bcl-2 family proteins, inhibition of phosphatidyl inositol 3-kinase and phosphorylation of Akt at Ser(473) and Thr(308)."( Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells.
Afaq, F; Khan, N; Mukhtar, H; Syed, DN, 2008
)
2.51
"Rats treated with fisetin (20 mg/kg-oral/ip) for short (30 min prior to surgery) and long (15 days prior to surgery followed by 1-day washout) duration were subjected to myocardial IR using Langendorf perfusion system."( Long-term administration of fisetin was not as effective as short term in ameliorating IR injury in isolated rat heart.
Boovarahan, SR; Kurian, GA; Prem, PN; Sivakumar, B, 2022
)
1.34
"Pretreatment with fisetin significantly alleviated the elevated levels of serum creatinine and blood urea nitrogen in LPS-treated mice. "( Flavonoid fisetin alleviates kidney inflammation and apoptosis via inhibiting Src-mediated NF-κB p65 and MAPK signaling pathways in septic AKI mice.
Fu, P; Guo, F; Huang, R; Ma, L; Ren, Q; Tao, S, 2020
)
1.29
"Treatment with fisetin significantly attenuated SCI-induced alternations in mechano-tactile and thermal allodynia, hyperalgesia and nerve conduction velocities. "( Neuroprotective potential of fisetin in an experimental model of spinal cord injury: via modulation of NF-κB/IκBα pathway.
Cui, J; Fan, J; Li, H; Tong, J; Zhang, J, 2021
)
1.27
"Treatment with fisetin, regardless of administration regimen, dose-dependently attenuated hyperuricemia-induced kidney injury as indicated by the improved renal function, preserved tissue architecture, and decreased urinary albumin-to-creatinine ratio. "( Natural flavonol fisetin attenuated hyperuricemic nephropathy via inhibiting IL-6/JAK2/STAT3 and TGF-β/SMAD3 signaling.
Fu, P; Guo, F; Ma, L; Ren, Q; Tao, S; Wang, B; Yang, L, 2021
)
1.31
"Pre-treatment with fisetin (50μM), fisetin (100μM), EGCG (100μM), quercetin (100μM), daidzein (50μM), and ECG (150μM) significantly reduced MNoV by 50.00±7.14 to 60.67±9.26%. "( Inhibitory mechanism of five natural flavonoids against murine norovirus.
Choi, C; Seo, DJ, 2017
)
0.78
"Treatment with fisetin alleviated hyperglycemia, hyperlipidemia and heart function markers, and minimized histological alterations in the myocardium."( Fisetin ameliorates oxidative stress, inflammation and apoptosis in diabetic cardiomyopathy.
Abukhalil, MH; Al Hroob, AM; Althunibat, OY; Bin-Jumah, M; Germoush, MO; Mahmoud, AM, 2019
)
2.3
"Post-treatment fisetin was found to suppress LPS-mediated release of HMGB1 and HMGB1-mediated cytoskeletal rearrangements."( Anti-septic effects of fisetin in vitro and in vivo.
Bae, JS; Han, MS; Kim, KM; Ku, SK; Yoo, H, 2014
)
1.05
"Treatment with fisetin also effectively inhibited LPS plus IFN-γ-induced nitric oxide (NO) production, and inducible nitric oxide synthase (iNOS) expression in microglial cells."( Regulatory effects of fisetin on microglial activation.
Chang, PC; Chen, JH; Chuang, JY; Lin, C; Lin, HY; Liu, YS; Lu, DY; Shen, YC; Tsai, CF; Wu, LH; Yeh, WL, 2014
)
1.06
"Treatment with fisetin successfully reduced the CoCl₂-mediated reactive oxygen species (ROS) production, which was accompanied by an increase in the cell viability of PC12 cells."( Cytoprotective effects of fisetin against hypoxia-induced cell death in PC12 cells.
Chen, PK; Chen, PY; Ho, CT; Ho, YR; Huang, SP; Tai, MH; Wu, MJ; Yen, JH, 2015
)
1.06
"Pretreatment with fisetin at doses of 20, 40 and 80 mg/kg (p.o.) for 7 days reversed LPS-induced alterations of the immobility time in both of these two tests."( The effects of fisetin on lipopolysaccharide-induced depressive-like behavior in mice.
Chen, L; Chen, Z; Jiang, X; Pan, J; Wang, G; Xu, L; Yu, X; Zhang, X, 2016
)
1.11
"Treatment with fisetin in athymic nude mice implanted with AR-positive CWR22Rupsilon1 human PCa cells resulted in inhibition of tumor growth and reduction in serum PSA levels."( A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice.
Abu Zaid, M; Afaq, F; Asim, M; Khan, N; Mukhtar, H, 2008
)
0.99
"Pretreatment with fisetin enhanced radiation-induced caspase-dependent apoptosis in HT-29 cells."( Enhancement of p53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetin.
Chen, WS; Chiu, SJ; Hsaio, CH; Lee, YJ; Tsai, YJ; Yen, JH; Yu, SH; Yu, YC, 2010
)
0.91
"Treatment with fisetin significantly reduced the degree of histological lesions, restored the levels of lipid peroxidation (LPO), enzymic and non-enzymic anti-oxidants in B(a)P-induced mice."( Fisetin, a novel flavonol attenuates benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice.
Ramesh, B; Ravichandran, N; Siva, GV; Suresh, G, 2011
)
2.15
"Treatment of fisetin (10-60 microM, 48 h) was found to result in a decrease in the viability of LNCaP, CWR22Rupsilon1 and PC-3 cells but had only minimal effects on normal prostate epithelial cells as assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide assay."( Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells.
Afaq, F; Khan, N; Mukhtar, H; Syed, DN, 2008
)
2.14

Toxicity

ExcerptReferenceRelevance
"Zinc neurotoxicity has been demonstrated in ischemic, seizure, hypoglycemic, and trauma-induced neuronal death where Zn(2+) is thought to be synaptically released and taken up in neighbouring neurons, reaching toxic concentrations."( Zinc neurotoxicity is dependent on intracellular NAD levels and the sirtuin pathway.
Cai, AL; Sheline, CT; Zipfel, GJ, 2006
)
0.33
" We observed that 150- and 500SiO₂-NP exerted no toxic effects on Calu-3 cells."( Mechanisms of toxicity of amorphous silica nanoparticles on human lung submucosal cells in vitro: protective effects of fisetin.
Corbalan, JJ; Inkielewicz-Stępniak, I; McCarthy, J; Radomski, MW, 2012
)
0.59
" Moreover, hemolysis and cell cytotoxicity testing showed that MPEG-PCL is biocompatible and safe for intravenous injection."( Anti-tumor activity and safety evaluation of fisetin-loaded methoxy poly(ethylene glycol)-poly(epsilon-caprolactone) nanoparticles.
Chen, X; Chu, B; Deng, X; Guo, G; Liang, J; Liao, J; Long, C; Luo, F; Peng, J; Qian, Z; Sun, J; Xie, C; Yang, Q; Zhang, L, 2014
)
0.66
"Nephrotoxicity is a dose-dependent side effect of cisplatin limiting its clinical usage in the field of cancer chemotherapy."( Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-κB activation and antioxidant defence.
Kalvala, AK; Koneru, M; Kuncha, M; Mahesh Kumar, J; Rachamalla, SS; Sahu, BD; Sistla, R, 2014
)
0.71
" We have shown in our earlier studies that gestational administration of 3,3',4',7-Tetrahydroxyflavone or Fisetin reduces the toxic effects of MeHg in the developing rat brain."( Extenuation of in utero toxic effects of MeHg in the developing neurons by Fisetin via modulating the expression of synaptic transmission and plasticity regulators in hippocampus of the rat offspring.
Jacob, S; Sumathi, T, 2019
)
0.96

Compound-Compound Interactions

Quercetin/fisetin enhances the anti-proliferative and anti-migratory activities in combination with naringenin in MCF7 and MDA-MB-231 human breast cancer cell lines. The goal of this study was to elucidate the antitumor effect of the flavonoid, f isetin, combined with the multikinase inhibitor, sorafenib.

ExcerptReferenceRelevance
" The goal of this study was to elucidate the antitumor effect of the flavonoid, fisetin, combined with the multikinase inhibitor, sorafenib, against human cervical cancer cells in vitro and in vivo."( Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
Cheng, CW; Hsieh, YH; Lin, CL; Lin, MT; Lin, TY; Tsai, JP; Wu, CC; Yang, SF, 2016
)
0.98
"In this study, cultured MCF7 and MDA-MB-231 cells were treated with different concentrations of quercetin/fisetin individually and in combination with naringenin."( Naringenin in combination with quercetin/fisetin shows synergistic anti-proliferative and migration reduction effects in breast cancer cell lines.
Jalalpour Choupanan, M; Reiisi, S; Shahbazi, S, 2023
)
1.39
"Our results indicate that quercetin/fisetin enhances the anti-proliferative and anti-migratory activities in combination with naringenin in MCF7 and MDA-MB-231 human breast cancer cell lines."( Naringenin in combination with quercetin/fisetin shows synergistic anti-proliferative and migration reduction effects in breast cancer cell lines.
Jalalpour Choupanan, M; Reiisi, S; Shahbazi, S, 2023
)
1.45

Bioavailability

Isoflavonoids and flavonoids were dissolved in a microemulsion to increase bioavailability. liposomal fisetin allowed a 47-fold increase in relative bioavailability compared to free f isetin. In silico pharmacokinetics, pharmacodynamics, and toxicity of fisatin are also comprehensively described.

ExcerptReferenceRelevance
" Resveratrol is sulphated, and the hepatic and duodenal sulphation might limit the bioavailability of this compound."( Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids.
De Santi, C; Mosca, F; Pacifici, GM; Pietrabissa, A; Spisni, R, 2000
)
0.31
" Glucuronidation may reduce the bioavailability of this compound however, flavonoids inhibit resveratrol glucuronidation and such an inhibition might improve the bioavailability of resveratrol."( Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver.
de Santi, C; Mosca, F; Pacifici, GM; Pietrabissa, A, 2000
)
0.31
" However, its relatively high EC(50) in cell based assays, low lipophilicity, high topological polar surface area (tPSA), and poor bioavailability suggest that there is room for medicinal chemical improvement."( Chemical modification of the multitarget neuroprotective compound fisetin.
Chiruta, C; Dargusch, R; Maher, P; Schubert, D, 2012
)
0.62
" However, when the fisetin nanoemulsion was administered intraperitoneally, a 24-fold increase in fisetin relative bioavailability was noted, compared to free fisetin."( Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice.
Arnaud, P; Brossard, D; Chabot, GG; Crauste-Manciet, S; Ragelle, H; Scherman, D; Seguin, J, 2012
)
1
" In vivo, liposomal fisetin allowed a 47-fold increase in relative bioavailability compared to free fisetin."( Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy.
Bessodes, M; Boyer, R; Brullé, L; Chabot, GG; Lu, YM; Mignet, N; Ramos Romano, M; Scherman, D; Seguin, J; Touil, YS, 2013
)
0.97
"The development of novel neuroprotective compounds to treat acute ischemic stroke (AIS) has been problematic and quite complicated, since many candidates that have been tested clinically lacked significant pleiotropic activity, were unable to effectively cross the blood brain barrier (BBB), had poor bioavailability or were toxic."( Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules.
Lapchak, PA, 2013
)
0.39
" The fisetin-Cys dimer complex showed also higher cytotoxicity to HeLa cells than free fisetin, indicating that the Cys dimer to improve bioavailability of fisetin."( Complexation of fisetin with novel cyclosophoroase dimer to improve solubility and bioavailability.
Cho, E; Choi, JM; Choi, Y; Jeong, D; Jeong, K; Jung, S, 2013
)
1.25
"Developed nanocochleates markedly improved anticancer efficacy, bioavailability and safety of fisetin."( Fisetin-loaded nanocochleates: formulation, characterisation, in vitro anticancer testing, bioavailability and biodistribution study.
Bothiraja, C; Pawar, AP; Shaikh, KS; Thorat, UH; Yojana, BD, 2014
)
2.06
" Its use in the pharmaceutical field is limited due to its poor aqueous solubility which results in poor bioavailability and poor permeability."( Preparation of albumin based nanoparticles for delivery of fisetin and evaluation of its cytotoxic activity.
Chaudhury, K; Chaudhury, S; Dasgupta, S; Ghosh, P; Jana, SK; Singha Roy, A, 2016
)
0.68
" In addition, we provide information regarding the chemistry, sources, bioavailability and clinical impacts of fisetin to provide a broad spectrum for the use of this compound as a new approach to the treatment of AD and PD."( Neuroprotective Effects of Fisetin in Alzheimer's and Parkinson's Diseases: From Chemistry to Medicine.
Braidy, N; Habtemariam, S; Manayi, A; Nabavi, SF; Nabavi, SM; Sureda, A, 2016
)
0.94
" The aim of the present study is to improve the oral bioavailability of FST by encapsulating into PLGA NPs (poly-lactide-co-glycolic acid nanoparticles) as a complex of HPβCD (hydroxyl propyl beta cyclodextrin) and to assess its anti-cancer activity against breast cancer cells."( Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HPβCD in polymeric nanoparticles.
Bhandi, MM; Borkar, RM; Gudem, S; Kadari, A; Kolapalli, VR; Kulhari, H; Sistla, R, 2017
)
0.7
" In addition, the increased bioavailability and sustained release of fisetin improved through conjugation and enhanced effect of fisetin through synergism on various cancers are also highlighted."( A review on the chemotherapeutic potential of fisetin: In vitro evidences.
Perumal, E; Raghunath, A; Sundarraj, K, 2018
)
0.97
" Efforts are being made to enhance the bioavailability of fisetin after oral administration to prevent and/or treat cancer of the liver, breast, ovary and other organs."( Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy.
Bishayee, A; Buttar, HS; Kashyap, D; Sak, K; Sharma, A; Tuli, HS, 2018
)
2.17
" The aim of the study was to develop FS loaded pluronic127 (PF)-folic acid (FA) conjugated micelles (FS-PF-FA) by the way of increasing solubility, bioavailability and active targetability of FS shall increase its therapeutic efficacy."( Development of fisetin-loaded folate functionalized pluronic micelles for breast cancer targeting.
Bothiraja, C; Pawar, A; Rajalakshmi, S; Shaikh, K; Singh, S, 2018
)
0.83
" 3-O-(N,N-Dibutylamino)propyl-3',4'-dimethoxyflavonol (42) emerged as the most promising derivative due to its substantially improved potency in cell models, superior bioavailability in rats, and good selectivity of inhibiting prostate cancer cell proliferation over non-neoplastic human epithelial cell proliferation."( Structure-activity relationship and pharmacokinetic studies of 3-O-substitutedflavonols as anti-prostate cancer agents.
Chen, G; Chen, QH; Fong, R; Gonzalez, A; Guo, S; Lee, M; Li, X; Rajaram, P; Wang, G; Zhang, C; Zhang, Q; Zheng, S, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" As solubility and bioavailability plays and important role in the pharmacological activity, in this research work we tried to improve the oral bioavailability of fisetin."( Enhanced oral bioavailability and neuroprotective effect of fisetin through its SNEDDS against rotenone-induced Parkinson's disease rat model.
Awasthi, A; Corrie, L; Kapoor, B; Kaur, J; Khurana, N; Khurana, S; Khursheed, R; Kumar, R; Sharma, N; Singh, SK; Verma, S; Vyas, M, 2020
)
1
" The bioavailability of fisetin in IFM and SSM was measured using the fluorescence method."( FIsetin Preserves Interfibrillar Mitochondria to Protect Against Myocardial Ischemia-Reperfusion Injury.
Boovarahan, SR; Kurian, GA; Prem, PN; Shanmugam, K; Sivakumar, B, 2022
)
2.47
" Moreover, in silico pharmacokinetics, pharmacodynamics, and toxicity of fisetin are also comprehensively described along with emerging novel drug delivery strategies for the amelioration of this flavonol bioavailability and chemical stability."( Fisetin as a Senotherapeutic Agent: Biopharmaceutical Properties and Crosstalk between Cell Senescence and Neuroprotection.
Carradori, S; Cataldi, A; Elsallabi, O; Gallorini, M; Patruno, A; Pesce, M, 2022
)
2.4
" Despite having excellent safety and efficacy profile, FS is very less explored to clinical research either as food supplement or, as therapeutic agent due to its poor aqueous solubility, low bioavailability and reduced blood brain barrier permeability."( Harnessing the therapeutic potential of fisetin and its nanoparticles: Journey so far and road ahead.
Adams, J; Awasthi, A; Chellappan, DK; Collet, T; Corrie, L; Devkota, HP; Dua, K; Gulati, M; Gupta, G; Gupta, PK; Gupta, S; Jha, NK; Khursheed, R; Kumar, R; Loebenberg, R; Porwal, O; Singh, SK; Vishwas, S, 2022
)
0.99
" However, the low water solubility and bioavailability of fisetin restrict its pharmaceutical applications."( Biochemical characterization of synthesized fisetin glucoside by dextransucrase from Leuconostoc mesenteroides NRRL B-1299CB4 with enhanced water solubility.
Kang, CG; Kim, D; Kim, H; Kim, SW; Moon, Y; Park, C, 2022
)
1.23
" A synergistic effect with anticancer drugs and strategies to improve the bioavailability are described."( The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment.
Allemailem, KS; Almatroodi, SA; Almatroudi, A; Khan, AA; Rahmani, AH, 2022
)
1.04
" Thus, novel drug delivery systems are needed to improve solubility and bioavailability of FIS."( Fisetin-loaded grape-derived nanoparticles improve anticancer efficacy in MOLT-4 cells.
Akbarzadelale, P; Gholipour, E; Khodadadi, M; Pourakbari, R; Samadi, P; Sarvarian, P; Shamsasenjan, K, 2023
)
2.35
" To attain this prospect, some limitations to this molecule, namely its poor bioavailability and solubility, must be addressed."( Fisetin derivatives exhibit enhanced anti-inflammatory activity and modulation of endoplasmic reticulum stress.
Correia da Silva, D; Ferreira, PMT; Jervis, PJ; Martins, JA; Pereira, DM; Valentão, P, 2023
)
2.35
"I absorption rate, with outstanding bioavailability index."( Design and development of new inhibitors against breast cancer, Monkeypox and Marburg virus by modification of natural Fisetin via in silico and SAR studies.
Akash, S; Alasmari, AF; Alharbi, M; Alshammari, A; Aziz, T; Emran, TB; Gonçalves Lima, CM; Naz, S; Rahman, MM; Sultana, S, 2023
)
1.12
" This study is aimed at preparing chitosan (CS)-based nanoparticles to yield fisetin with improved bioavailability features."( Evaluation of the anti-inflammatory activity of fisetin-loaded nanoparticles in an in vitro model of osteoarthritis.
Mirmohammadkhani, M; Nabizadeh, Z; Nasrabadi, D; Nasrollahzadeh, M; Shabani, AA, 2023
)
1.39
" However, their low bioavailability makes them complex compounds to use for therapeutic purposes."( Fisetin-In Search of Better Bioavailability-From Macro to Nano Modifications: A Review.
Cielecka-Piontek, J; Szymczak, J, 2023
)
2.35
" This review also describes a growing number of nanodelivery systems designed to improve the bioavailability and solubility of this natural compound."( Role of Fisetin in Selected Malignant Neoplasms in Women.
Antoszczak, M; Huczyński, A; Kacprzak, K; Markowska, A; Markowska, J, 2023
)
1.34

Dosage Studied

The dosage of fisetin and co-morbidities like diabetes and obesity are found to be detrimental factors for cardioprotection.

ExcerptRelevanceReference
" This facilitates their ready acceptance as dietary supplements with no requirements of special dosage and concerns over long-term usage."( Encapsulation of Nutraceutical Ingredients in Liposomes and Their Potential for Cancer Treatment.
Anandharamakrishnan, C; Dutta, S; Moses, JA,
)
0.13
" Moreover, the dosage of fisetin and co-morbidities like diabetes and obesity are found to be detrimental factors for cardioprotection."( Recent advances in potential of Fisetin in the management of myocardial ischemia-reperfusion injury-A systematic review.
Boovarahan, SR; Kurian, GA; Prem, PN; Sivakumar, B, 2022
)
1.31
" From 4-13 months of age, C57BL/6 male and female mice received monthly oral dosing of either 100 mg/kg Fisetin or a 5 mg/kg Dasatinib (D) plus 50 mg/kg Quercetin (Q) cocktail."( Sexual dimorphic metabolic and cognitive responses of C57BL/6 mice to Fisetin or Dasatinib and quercetin cocktail oral treatment.
Bartke, A; Fang, Y; Hascup, ER; Hascup, KN; McFadden, S; Medina, D; Peck, MR; Quinn, K; Stockwell, R, 2023
)
1.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (4 Product(s))

Product Categories

Product CategoryProducts
Vitamins & Supplements4

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
1Life Science NAD+ Longevity Cardiovascular Support -- 60 Veggie Caps1Life ScienceVitamins & SupplementsApigenin, Fisetin, Vitamin B9, NAD +, Vitamin B3, NMN, Vitamin B6, Quercetin, Vitamin B62024-11-29 10:47:42
Nutri Resverperine+ Trans-Resveratrol with Black Pepper & Fisetin -- 1000 mg - 60 Vegan CapsulesNutriVitamins & SupplementsFisetin, Trans-Resveratrol2024-11-29 10:47:42
Nutri SenoFi - Fisetin -- 500 mg - 60 Vegan CapsulesNutriVitamins & SupplementsFisetin2024-11-29 10:47:42
Nutri SenoFi Fisetin -- 500 mg - 32 Vegan CapsulesNutriVitamins & SupplementsFisetin2024-11-29 10:47:42

Roles (6)

RoleDescription
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitorA topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
tetrahydroxyflavoneAny hydroxyflavone carrying four hydroxy substituents.
3'-hydroxyflavonoidAny hydroxyflavone with a hydroxy substituent at position 3'.
7-hydroxyflavonolAny flavonol carrying a 7-hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (90)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency9.98880.003245.467312,589.2998AID2517; AID2572
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency25.05940.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency16.75410.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency16.75410.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency14.12540.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency3.16230.125919.1169125.8920AID2549
endonuclease IVEscherichia coliPotency25.11890.707912.432431.6228AID2565
15-lipoxygenase, partialHomo sapiens (human)Potency3.50360.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency17.70660.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency6.47760.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency12.58930.011212.4002100.0000AID1030
EWS/FLI fusion proteinHomo sapiens (human)Potency17.75750.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
67.9K proteinVaccinia virusPotency28.18380.00018.4406100.0000AID720579
hemoglobin subunit betaHomo sapiens (human)Potency31.62280.31629.086131.6228AID930
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency13.96680.316212.443531.6228AID924
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency15.84891.000012.232631.6228AID1452
cytochrome P450 2C9 precursorHomo sapiens (human)Potency22.53580.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency20.26770.001815.663839.8107AID894
mitogen-activated protein kinase 1Homo sapiens (human)Potency10.26630.039816.784239.8107AID1724; AID995
DNA polymerase kappa isoform 1Homo sapiens (human)Potency0.48020.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency32.46480.031610.279239.8107AID884; AID885
caspase-1 isoform alpha precursorHomo sapiens (human)Potency20.48390.000311.448431.6228AID900
lamin isoform A-delta10Homo sapiens (human)Potency22.38720.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency15.84890.316212.765731.6228AID881
Integrin beta-3Homo sapiens (human)Potency13.96680.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency13.96680.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Glutamate receptor 1Rattus norvegicus (Norway rat)Potency0.89130.01418.602439.8107AID2572
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.89130.001551.739315,848.9004AID2572
Glutamate receptor 3Rattus norvegicus (Norway rat)Potency0.89130.01418.602439.8107AID2572
Glutamate receptor 4Rattus norvegicus (Norway rat)Potency0.89130.01418.602439.8107AID2572
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency20.86400.00638.235039.8107AID881; AID883
Caspase-7Homo sapiens (human)Potency17.90083.981118.585631.6228AID889
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency11.22021.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
CREB-binding proteinHomo sapiens (human)Potency17.04530.02822.360012.5893AID907; AID916
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency32.46481.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain B, Cell division protein kinase 6Homo sapiens (human)IC50 (µMol)0.85000.85000.85000.8500AID977608
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)IC50 (µMol)100.00000.03201.46494.8000AID309801
G2/mitotic-specific cyclin-B2Homo sapiens (human)IC50 (µMol)0.79000.00251.817210.0000AID241206
Cyclin-dependent kinase 1Homo sapiens (human)IC50 (µMol)0.79000.00041.345210.0000AID241206
Alpha-amylase 1A Homo sapiens (human)IC50 (µMol)19.60000.50004.02039.6400AID1798320; AID404692
Serine/threonine-protein kinase pim-1Homo sapiens (human)IC50 (µMol)0.85000.00040.887110.0000AID1798717
Pyruvate kinase PKMHomo sapiens (human)IC50 (µMol)0.90000.50002.788610.0000AID1881916
G2/mitotic-specific cyclin-B1Homo sapiens (human)IC50 (µMol)0.79000.00131.451810.0000AID241206
G2/mitotic-specific cyclin-BMarthasterias glacialis (spiny starfish)IC50 (µMol)0.65750.00402.10939.4000AID1796044
Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)IC50 (µMol)1.40000.04002.099810.0000AID309799
Polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)IC50 (µMol)0.95000.10002.452310.0000AID309798
Glycogen synthase kinase-3 betaRattus norvegicus (Norway rat)IC50 (µMol)0.65750.00401.51657.2000AID1796044
Casein kinase II subunit alpha'Homo sapiens (human)IC50 (µMol)0.56670.00031.432010.0000AID1247842; AID1572646; AID779050
Casein kinase II subunit alpha'Homo sapiens (human)Ki0.17000.00020.90117.6700AID1294141
AcetylcholinesteraseHomo sapiens (human)Ki100.20000.00001.27869.7300AID441660
Cyclin-dependent kinase 2Homo sapiens (human)IC50 (µMol)5.00000.00041.044410.0000AID298693
CruzipainTrypanosoma cruziIC50 (µMol)45.00000.00022.04508.0000AID444614; AID444615
Testosterone 17-beta-dehydrogenase 3Homo sapiens (human)IC50 (µMol)32.40000.00261.76469.3000AID1799665
Tyrosine-protein kinase SYKHomo sapiens (human)IC50 (µMol)15.00000.00010.826010.0000AID701071
1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12IC50 (µMol)3.50000.02000.74213.5000AID1801043
Xanthine dehydrogenase/oxidaseHomo sapiens (human)IC50 (µMol)4.33000.00132.81389.8200AID399340
Glycogen synthase kinase-3 alphaHomo sapiens (human)IC50 (µMol)0.42000.00101.22499.1000AID240981
Glycogen synthase kinase-3 betaHomo sapiens (human)IC50 (µMol)0.42000.00060.801310.0000AID240981
Mitogen-activated protein kinase 10Homo sapiens (human)IC50 (µMol)2.65000.00201.703510.0000AID1799639
Casein kinase II subunit betaHomo sapiens (human)IC50 (µMol)0.56670.00031.487510.0000AID1247842; AID1572646; AID779050
Casein kinase II subunit betaHomo sapiens (human)Ki0.17000.00021.11247.6700AID1294141
Casein kinase II subunit alphaHomo sapiens (human)IC50 (µMol)0.56670.00051.333210.0000AID1247842; AID1572646; AID779050
Casein kinase II subunit alphaHomo sapiens (human)Ki0.26000.00041.09847.6700AID1294141; AID1539764
Cyclin-dependent kinase 6Homo sapiens (human)IC50 (µMol)0.69600.00190.86547.2000AID1796044; AID242481
Cyclin-dependent-like kinase 5 Homo sapiens (human)IC50 (µMol)0.64000.00021.183210.0000AID1796044; AID241232
Cyclin homologHerpesvirus saimiri (strain 11)IC50 (µMol)0.65750.08002.47007.2000AID1796044
Lactoylglutathione lyaseHomo sapiens (human)Ki13.18260.00122.59479.1400AID74123
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)IC50 (µMol)0.64000.00101.289810.0000AID1796044; AID241232
Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)2.65000.00010.72667.8000AID1799639
Integrase Human immunodeficiency virus 1IC50 (µMol)18.45000.00051.544310.0000AID93507; AID93508
Casein kinase II subunit alpha 3Homo sapiens (human)IC50 (µMol)0.35000.00151.966410.0000AID1572646
G2/mitotic-specific cyclin-B3Homo sapiens (human)IC50 (µMol)0.79000.00251.817210.0000AID241206
Enoyl-acyl-carrier protein reductase Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)1.00000.06601.549910.0000AID265759; AID494830
3-oxoacyl-acyl-carrier protein reductase Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)4.10000.30003.772710.0000AID265760
Beta-hydroxyacyl-ACP dehydratase precursor (Fatty acid synthesis protein)Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)2.00000.03002.94428.0000AID265758
Aurora kinase BHomo sapiens (human)IC50 (µMol)2.63000.00030.96349.8000AID1801097
Cyclin-dependent kinase 1Oryzias latipes (Japanese medaka)IC50 (µMol)0.65750.00402.10939.4000AID1796044
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein kinase SYKHomo sapiens (human)EC50 (µMol)19.00000.00200.62905.0000AID701064
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Serine/threonine-protein kinase pim-1Homo sapiens (human)-Log IC500.07000.01000.17860.4700AID311148
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (616)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
in utero embryonic developmentG2/mitotic-specific cyclin-B2Homo sapiens (human)
spindle assembly involved in female meiosis IG2/mitotic-specific cyclin-B2Homo sapiens (human)
G2/MI transition of meiotic cell cycleG2/mitotic-specific cyclin-B2Homo sapiens (human)
regulation of growthG2/mitotic-specific cyclin-B2Homo sapiens (human)
T cell homeostasisG2/mitotic-specific cyclin-B2Homo sapiens (human)
thymus developmentG2/mitotic-specific cyclin-B2Homo sapiens (human)
cell divisionG2/mitotic-specific cyclin-B2Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityG2/mitotic-specific cyclin-B2Homo sapiens (human)
mitotic cell cycle phase transitionG2/mitotic-specific cyclin-B2Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 1Homo sapiens (human)
microtubule cytoskeleton organizationCyclin-dependent kinase 1Homo sapiens (human)
DNA replicationCyclin-dependent kinase 1Homo sapiens (human)
DNA repairCyclin-dependent kinase 1Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IICyclin-dependent kinase 1Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 1Homo sapiens (human)
apoptotic processCyclin-dependent kinase 1Homo sapiens (human)
DNA damage responseCyclin-dependent kinase 1Homo sapiens (human)
mitotic nuclear membrane disassemblyCyclin-dependent kinase 1Homo sapiens (human)
centrosome cycleCyclin-dependent kinase 1Homo sapiens (human)
pronuclear fusionCyclin-dependent kinase 1Homo sapiens (human)
response to xenobiotic stimulusCyclin-dependent kinase 1Homo sapiens (human)
response to toxic substanceCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of gene expressionCyclin-dependent kinase 1Homo sapiens (human)
negative regulation of gene expressionCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 1Homo sapiens (human)
regulation of Schwann cell differentiationCyclin-dependent kinase 1Homo sapiens (human)
response to amineCyclin-dependent kinase 1Homo sapiens (human)
response to activityCyclin-dependent kinase 1Homo sapiens (human)
cell migrationCyclin-dependent kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationCyclin-dependent kinase 1Homo sapiens (human)
chromosome condensationCyclin-dependent kinase 1Homo sapiens (human)
epithelial cell differentiationCyclin-dependent kinase 1Homo sapiens (human)
animal organ regenerationCyclin-dependent kinase 1Homo sapiens (human)
protein localization to kinetochoreCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of protein import into nucleusCyclin-dependent kinase 1Homo sapiens (human)
regulation of circadian rhythmCyclin-dependent kinase 1Homo sapiens (human)
negative regulation of apoptotic processCyclin-dependent kinase 1Homo sapiens (human)
response to ethanolCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 1Homo sapiens (human)
regulation of embryonic developmentCyclin-dependent kinase 1Homo sapiens (human)
response to cadmium ionCyclin-dependent kinase 1Homo sapiens (human)
response to copper ionCyclin-dependent kinase 1Homo sapiens (human)
symbiont entry into host cellCyclin-dependent kinase 1Homo sapiens (human)
fibroblast proliferationCyclin-dependent kinase 1Homo sapiens (human)
rhythmic processCyclin-dependent kinase 1Homo sapiens (human)
response to axon injuryCyclin-dependent kinase 1Homo sapiens (human)
cell divisionCyclin-dependent kinase 1Homo sapiens (human)
ventricular cardiac muscle cell developmentCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of mitotic sister chromatid segregationCyclin-dependent kinase 1Homo sapiens (human)
protein-containing complex assemblyCyclin-dependent kinase 1Homo sapiens (human)
cellular response to hydrogen peroxideCyclin-dependent kinase 1Homo sapiens (human)
ERK1 and ERK2 cascadeCyclin-dependent kinase 1Homo sapiens (human)
cellular response to organic cyclic compoundCyclin-dependent kinase 1Homo sapiens (human)
Golgi disassemblyCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of protein localization to nucleusCyclin-dependent kinase 1Homo sapiens (human)
regulation of attachment of mitotic spindle microtubules to kinetochoreCyclin-dependent kinase 1Homo sapiens (human)
microtubule cytoskeleton organization involved in mitosisCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of mitochondrial ATP synthesis coupled electron transportCyclin-dependent kinase 1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingCyclin-dependent kinase 1Homo sapiens (human)
protein deubiquitinationCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
oligosaccharide metabolic processAlpha-amylase 1A Homo sapiens (human)
carbohydrate metabolic processAlpha-amylase 1A Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of transmembrane transporter activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of innate immune responseSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
vitamin D receptor signaling pathwaySerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular response to type II interferonSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of brown fat cell differentiationSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of hematopoietic stem cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of TORC1 signalingSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardioblast proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular detoxificationSerine/threonine-protein kinase pim-1Homo sapiens (human)
programmed cell deathPyruvate kinase PKMHomo sapiens (human)
canonical glycolysisPyruvate kinase PKMHomo sapiens (human)
positive regulation of sprouting angiogenesisPyruvate kinase PKMHomo sapiens (human)
positive regulation of cytoplasmic translationPyruvate kinase PKMHomo sapiens (human)
glycolytic processPyruvate kinase PKMHomo sapiens (human)
cellular response to insulin stimulusPyruvate kinase PKMHomo sapiens (human)
G2/M transition of mitotic cell cycleG2/mitotic-specific cyclin-B1Homo sapiens (human)
in utero embryonic developmentG2/mitotic-specific cyclin-B1Homo sapiens (human)
mitotic spindle organizationG2/mitotic-specific cyclin-B1Homo sapiens (human)
mitotic metaphase chromosome alignmentG2/mitotic-specific cyclin-B1Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleG2/mitotic-specific cyclin-B1Homo sapiens (human)
positive regulation of mitotic cell cycleG2/mitotic-specific cyclin-B1Homo sapiens (human)
positive regulation of fibroblast proliferationG2/mitotic-specific cyclin-B1Homo sapiens (human)
cell divisionG2/mitotic-specific cyclin-B1Homo sapiens (human)
positive regulation of attachment of spindle microtubules to kinetochoreG2/mitotic-specific cyclin-B1Homo sapiens (human)
regulation of mitotic cell cycle spindle assembly checkpointG2/mitotic-specific cyclin-B1Homo sapiens (human)
positive regulation of mitochondrial ATP synthesis coupled electron transportG2/mitotic-specific cyclin-B1Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityG2/mitotic-specific cyclin-B1Homo sapiens (human)
mitotic cell cycle phase transitionG2/mitotic-specific cyclin-B1Homo sapiens (human)
ossificationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
negative regulation of adaptive immune responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylethanolamine biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of cell-substrate adhesionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
bone mineralizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of actin filament polymerizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
response to endoplasmic reticulum stressPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to interleukin-13Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
wound healingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
apoptotic cell clearancePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to calcium ionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of engulfment of apoptotic cellPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of muscle cell apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
unsaturated fatty acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
superoxide anion generationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
establishment of skin barrierPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of platelet aggregationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin B4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
double-strand break repairCasein kinase II subunit alpha'Homo sapiens (human)
apoptotic processCasein kinase II subunit alpha'Homo sapiens (human)
spermatogenesisCasein kinase II subunit alpha'Homo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
cerebral cortex developmentCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alpha'Homo sapiens (human)
liver regenerationCasein kinase II subunit alpha'Homo sapiens (human)
regulation of mitophagyCasein kinase II subunit alpha'Homo sapiens (human)
positive regulation of protein targeting to mitochondrionCasein kinase II subunit alpha'Homo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 2Homo sapiens (human)
DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
DNA repairCyclin-dependent kinase 2Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 2Homo sapiens (human)
DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
potassium ion transportCyclin-dependent kinase 2Homo sapiens (human)
centriole replicationCyclin-dependent kinase 2Homo sapiens (human)
Ras protein signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of heterochromatin formationCyclin-dependent kinase 2Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiationCyclin-dependent kinase 2Homo sapiens (human)
telomere maintenance in response to DNA damageCyclin-dependent kinase 2Homo sapiens (human)
post-translational protein modificationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
centrosome duplicationCyclin-dependent kinase 2Homo sapiens (human)
cell divisionCyclin-dependent kinase 2Homo sapiens (human)
meiotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
cellular response to nitric oxideCyclin-dependent kinase 2Homo sapiens (human)
cellular senescenceCyclin-dependent kinase 2Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processCyclin-dependent kinase 2Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 2Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 2Homo sapiens (human)
androgen biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
male genitalia developmentTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
steroid biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
protein import into nucleusTyrosine-protein kinase SYKHomo sapiens (human)
regulation of DNA-binding transcription factor activityTyrosine-protein kinase SYKHomo sapiens (human)
angiogenesisTyrosine-protein kinase SYKHomo sapiens (human)
cell activationTyrosine-protein kinase SYKHomo sapiens (human)
lymph vessel developmentTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of receptor internalizationTyrosine-protein kinase SYKHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase SYKHomo sapiens (human)
macrophage activation involved in immune responseTyrosine-protein kinase SYKHomo sapiens (human)
neutrophil activation involved in immune responseTyrosine-protein kinase SYKHomo sapiens (human)
leukocyte activation involved in immune responseTyrosine-protein kinase SYKHomo sapiens (human)
serotonin secretion by plateletTyrosine-protein kinase SYKHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase SYKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase SYKHomo sapiens (human)
leukocyte cell-cell adhesionTyrosine-protein kinase SYKHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
animal organ morphogenesisTyrosine-protein kinase SYKHomo sapiens (human)
regulation of platelet activationTyrosine-protein kinase SYKHomo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase SYKHomo sapiens (human)
leukotriene biosynthetic processTyrosine-protein kinase SYKHomo sapiens (human)
calcium-mediated signalingTyrosine-protein kinase SYKHomo sapiens (human)
platelet activationTyrosine-protein kinase SYKHomo sapiens (human)
B cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
neutrophil chemotaxisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of protein-containing complex assemblyTyrosine-protein kinase SYKHomo sapiens (human)
receptor internalizationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of type I interferon productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of granulocyte macrophage colony-stimulating factor productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-10 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-12 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-3 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-4 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-6 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-8 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of mast cell cytokine productionTyrosine-protein kinase SYKHomo sapiens (human)
regulation of superoxide anion generationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of superoxide anion generationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of cell adhesion mediated by integrinTyrosine-protein kinase SYKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase SYKHomo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase SYKHomo sapiens (human)
interleukin-3-mediated signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
gamma-delta T cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
defense response to bacteriumTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase SYKHomo sapiens (human)
mast cell degranulationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of mast cell degranulationTyrosine-protein kinase SYKHomo sapiens (human)
regulation of neutrophil degranulationTyrosine-protein kinase SYKHomo sapiens (human)
beta selectionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of MAPK cascadeTyrosine-protein kinase SYKHomo sapiens (human)
innate immune responseTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of B cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of gamma-delta T cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of bone resorptionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of alpha-beta T cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of alpha-beta T cell proliferationTyrosine-protein kinase SYKHomo sapiens (human)
blood vessel morphogenesisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase SYKHomo sapiens (human)
regulation of phagocytosisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of calcium-mediated signalingTyrosine-protein kinase SYKHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of killing of cells of another organismTyrosine-protein kinase SYKHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to molecule of fungal originTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to lipidTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of monocyte chemotactic protein-1 productionTyrosine-protein kinase SYKHomo sapiens (human)
regulation of arachidonic acid secretionTyrosine-protein kinase SYKHomo sapiens (human)
regulation of platelet aggregationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of cold-induced thermogenesisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of TORC1 signalingTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to lectinTyrosine-protein kinase SYKHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
isopentenyl diphosphate biosynthetic process, methylerythritol 4-phosphate pathway1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
isoprenoid biosynthetic process1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
isopentenyl diphosphate biosynthetic process, methylerythritol 4-phosphate pathway1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
isopentenyl diphosphate biosynthetic process, methylerythritol 4-phosphate pathway involved in terpenoid biosynthetic process1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
allantoin metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of protein phosphorylationXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell proliferationXanthine dehydrogenase/oxidaseHomo sapiens (human)
guanine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
inosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyinosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
adenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyadenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyguanosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
AMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
IMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
lactationXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of gene expressionXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron-sulfur cluster assemblyXanthine dehydrogenase/oxidaseHomo sapiens (human)
amide catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell differentiationXanthine dehydrogenase/oxidaseHomo sapiens (human)
GMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dGMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dAMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of p38MAPK cascadeXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathwayXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vasculogenesisXanthine dehydrogenase/oxidaseHomo sapiens (human)
regulation of systemic arterial blood pressureGlycogen synthase kinase-3 alphaHomo sapiens (human)
cardiac left ventricle morphogenesisGlycogen synthase kinase-3 alphaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
nervous system developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of UDP-glucose catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
Wnt signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
cell migrationGlycogen synthase kinase-3 alphaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to insulin stimulusGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 alphaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of heart contractionGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glucose importGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to lithium ionGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to glucocorticoid stimulusGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
autosome genomic imprintingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of mitophagyGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of amyloid-beta formationGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein targeting to mitochondrionGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen synthase activity, transferring glucose-1-phosphateGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
ER overload responseGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of apoptotic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
epithelial to mesenchymal transitionGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell-matrix adhesionGlycogen synthase kinase-3 betaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrion organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 betaHomo sapiens (human)
hippocampus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
establishment of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
maintenance of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of cell migrationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axon extensionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of phosphoprotein phosphatase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule-based processGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 betaHomo sapiens (human)
regulation of circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of GTPase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of osteoblast differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cilium assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein autophosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of dendrite morphogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axonogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeGlycogen synthase kinase-3 betaHomo sapiens (human)
superior temporal gyrus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to retinoic acidGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 betaHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule anchoring at centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of cellular response to heatGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein localization to nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of long-term synaptic potentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein acetylationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to ciliumGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of dopaminergic neuron differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to amyloid-betaGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complex disassemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of mesenchymal stem cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 10Homo sapiens (human)
signal transductionMitogen-activated protein kinase 10Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 10Homo sapiens (human)
response to light stimulusMitogen-activated protein kinase 10Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 10Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 10Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 10Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 10Homo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
signal transductionCasein kinase II subunit betaHomo sapiens (human)
negative regulation of cell population proliferationCasein kinase II subunit betaHomo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit betaHomo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit betaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit betaHomo sapiens (human)
positive regulation of activin receptor signaling pathwayCasein kinase II subunit betaHomo sapiens (human)
adiponectin-activated signaling pathwayCasein kinase II subunit betaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationCasein kinase II subunit betaHomo sapiens (human)
regulation of DNA bindingCasein kinase II subunit betaHomo sapiens (human)
positive regulation of SMAD protein signal transductionCasein kinase II subunit betaHomo sapiens (human)
endothelial tube morphogenesisCasein kinase II subunit betaHomo sapiens (human)
protein-containing complex assemblyCasein kinase II subunit betaHomo sapiens (human)
symbiont-mediated disruption of host cell PML bodyCasein kinase II subunit betaHomo sapiens (human)
negative regulation of viral life cycleCasein kinase II subunit betaHomo sapiens (human)
double-strand break repairCasein kinase II subunit alphaHomo sapiens (human)
protein phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
DNA damage responseCasein kinase II subunit alphaHomo sapiens (human)
signal transductionCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell population proliferationCasein kinase II subunit alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of translationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell growthCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
rhythmic processCasein kinase II subunit alphaHomo sapiens (human)
protein stabilizationCasein kinase II subunit alphaHomo sapiens (human)
chaperone-mediated protein foldingCasein kinase II subunit alphaHomo sapiens (human)
symbiont-mediated disruption of host cell PML bodyCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of aggrephagyCasein kinase II subunit alphaHomo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
regulation of cell cycleCasein kinase II subunit alphaHomo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 6Homo sapiens (human)
positive regulation of cell-matrix adhesionCyclin-dependent kinase 6Homo sapiens (human)
type B pancreatic cell developmentCyclin-dependent kinase 6Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 6Homo sapiens (human)
Notch signaling pathwayCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cell population proliferationCyclin-dependent kinase 6Homo sapiens (human)
response to virusCyclin-dependent kinase 6Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 6Homo sapiens (human)
positive regulation of gene expressionCyclin-dependent kinase 6Homo sapiens (human)
astrocyte developmentCyclin-dependent kinase 6Homo sapiens (human)
dentate gyrus developmentCyclin-dependent kinase 6Homo sapiens (human)
lateral ventricle developmentCyclin-dependent kinase 6Homo sapiens (human)
T cell differentiation in thymusCyclin-dependent kinase 6Homo sapiens (human)
gliogenesisCyclin-dependent kinase 6Homo sapiens (human)
cell dedifferentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of myeloid cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
regulation of erythrocyte differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of monocyte differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of osteoblast differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cell cycleCyclin-dependent kinase 6Homo sapiens (human)
positive regulation of fibroblast proliferationCyclin-dependent kinase 6Homo sapiens (human)
generation of neuronsCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of epithelial cell proliferationCyclin-dependent kinase 6Homo sapiens (human)
cell divisionCyclin-dependent kinase 6Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 6Homo sapiens (human)
hematopoietic stem cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
regulation of hematopoietic stem cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
regulation of cell motilityCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cellular senescenceCyclin-dependent kinase 6Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 6Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 6Homo sapiens (human)
signal transductionCyclin-dependent kinase 6Homo sapiens (human)
microtubule cytoskeleton organizationCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron migrationCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic transmission, dopaminergicCyclin-dependent-like kinase 5 Homo sapiens (human)
protein phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
intracellular protein transportCyclin-dependent-like kinase 5 Homo sapiens (human)
cell-matrix adhesionCyclin-dependent-like kinase 5 Homo sapiens (human)
chemical synaptic transmissionCyclin-dependent-like kinase 5 Homo sapiens (human)
synapse assemblyCyclin-dependent-like kinase 5 Homo sapiens (human)
skeletal muscle tissue developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
motor neuron axon guidanceCyclin-dependent-like kinase 5 Homo sapiens (human)
visual learningCyclin-dependent-like kinase 5 Homo sapiens (human)
Schwann cell developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle exocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of macroautophagyCyclin-dependent-like kinase 5 Homo sapiens (human)
phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
peptidyl-threonine phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
sensory perception of painCyclin-dependent-like kinase 5 Homo sapiens (human)
cerebellar cortex formationCyclin-dependent-like kinase 5 Homo sapiens (human)
hippocampus developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
layer formation in cerebral cortexCyclin-dependent-like kinase 5 Homo sapiens (human)
central nervous system neuron developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
corpus callosum developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron differentiationCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of cell migrationCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of axon extensionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron projection developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of protein ubiquitinationCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of synaptic plasticityCyclin-dependent-like kinase 5 Homo sapiens (human)
receptor catabolic processCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic transmission, glutamatergicCyclin-dependent-like kinase 5 Homo sapiens (human)
protein localization to synapseCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
receptor clusteringCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of neuron apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of cell cycleCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of proteolysisCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of DNA-templated transcriptionCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of calcium ion-dependent exocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of protein export from nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
behavioral response to cocaineCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic plasticityCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle endocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
rhythmic processCyclin-dependent-like kinase 5 Homo sapiens (human)
axon extensionCyclin-dependent-like kinase 5 Homo sapiens (human)
oligodendrocyte differentiationCyclin-dependent-like kinase 5 Homo sapiens (human)
dendrite morphogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
cell divisionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of cell cycleCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCyclin-dependent-like kinase 5 Homo sapiens (human)
excitatory postsynaptic potentialCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of dendritic spine morphogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
calcium ion importCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of protein targeting to membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of protein localization to plasma membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic vesicle recyclingCyclin-dependent-like kinase 5 Homo sapiens (human)
cellular response to amyloid-betaCyclin-dependent-like kinase 5 Homo sapiens (human)
axonogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle transportCyclin-dependent-like kinase 5 Homo sapiens (human)
carbohydrate metabolic processLactoylglutathione lyaseHomo sapiens (human)
regulation of transcription by RNA polymerase IILactoylglutathione lyaseHomo sapiens (human)
glutathione metabolic processLactoylglutathione lyaseHomo sapiens (human)
methylglyoxal metabolic processLactoylglutathione lyaseHomo sapiens (human)
osteoclast differentiationLactoylglutathione lyaseHomo sapiens (human)
negative regulation of apoptotic processLactoylglutathione lyaseHomo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
microtubule cytoskeleton organizationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuron migrationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuron cell-cell adhesionCyclin-dependent kinase 5 activator 1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayCyclin-dependent kinase 5 activator 1Homo sapiens (human)
axon guidanceCyclin-dependent kinase 5 activator 1Homo sapiens (human)
axonal fasciculationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
brain developmentCyclin-dependent kinase 5 activator 1Homo sapiens (human)
embryo development ending in birth or egg hatchingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
regulation of macroautophagyCyclin-dependent kinase 5 activator 1Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
peptidyl-threonine phosphorylationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
cerebellum developmentCyclin-dependent kinase 5 activator 1Homo sapiens (human)
superior olivary nucleus maturationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
hippocampus developmentCyclin-dependent kinase 5 activator 1Homo sapiens (human)
layer formation in cerebral cortexCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuron differentiationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
positive regulation of microtubule polymerizationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuron projection developmentCyclin-dependent kinase 5 activator 1Homo sapiens (human)
regulation of actin cytoskeleton organizationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayCyclin-dependent kinase 5 activator 1Homo sapiens (human)
positive regulation of neuron apoptotic processCyclin-dependent kinase 5 activator 1Homo sapiens (human)
regulation of neuron differentiationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionCyclin-dependent kinase 5 activator 1Homo sapiens (human)
ephrin receptor signaling pathwayCyclin-dependent kinase 5 activator 1Homo sapiens (human)
rhythmic processCyclin-dependent kinase 5 activator 1Homo sapiens (human)
regulation of dendritic spine morphogenesisCyclin-dependent kinase 5 activator 1Homo sapiens (human)
G1 to G0 transition involved in cell differentiationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
positive regulation of protein targeting to membraneCyclin-dependent kinase 5 activator 1Homo sapiens (human)
regulation of synaptic vesicle cycleCyclin-dependent kinase 5 activator 1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 14Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase 14Homo sapiens (human)
cell morphogenesisMitogen-activated protein kinase 14Homo sapiens (human)
cartilage condensationMitogen-activated protein kinase 14Homo sapiens (human)
angiogenesisMitogen-activated protein kinase 14Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
placenta developmentMitogen-activated protein kinase 14Homo sapiens (human)
response to dietary excessMitogen-activated protein kinase 14Homo sapiens (human)
chondrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusMitogen-activated protein kinase 14Homo sapiens (human)
glucose metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 14Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 14Homo sapiens (human)
signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
skeletal muscle tissue developmentMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myotube differentiationMitogen-activated protein kinase 14Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 14Homo sapiens (human)
fatty acid oxidationMitogen-activated protein kinase 14Homo sapiens (human)
platelet activationMitogen-activated protein kinase 14Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 14Homo sapiens (human)
osteoclast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 14Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
response to muramyl dipeptideMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 14Homo sapiens (human)
response to insulinMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of hippo signalingMitogen-activated protein kinase 14Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMitogen-activated protein kinase 14Homo sapiens (human)
response to muscle stretchMitogen-activated protein kinase 14Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of protein import into nucleusMitogen-activated protein kinase 14Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
glucose importMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of glucose importMitogen-activated protein kinase 14Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
stem cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
striated muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 14Homo sapiens (human)
bone developmentMitogen-activated protein kinase 14Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipoteichoic acidMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to ionizing radiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of brown fat cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 14Homo sapiens (human)
stress-induced premature senescenceMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 14Homo sapiens (human)
regulation of synaptic membrane adhesionMitogen-activated protein kinase 14Homo sapiens (human)
regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast fusionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphorylationCasein kinase II subunit alpha 3Homo sapiens (human)
positive regulation of cell population proliferationCasein kinase II subunit alpha 3Homo sapiens (human)
positive regulation of cell growthCasein kinase II subunit alpha 3Homo sapiens (human)
positive regulation of protein catabolic processCasein kinase II subunit alpha 3Homo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alpha 3Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alpha 3Homo sapiens (human)
regulation of cell cycleCasein kinase II subunit alpha 3Homo sapiens (human)
cell divisionG2/mitotic-specific cyclin-B3Homo sapiens (human)
meiotic cell cycleG2/mitotic-specific cyclin-B3Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityG2/mitotic-specific cyclin-B3Homo sapiens (human)
mitotic cell cycle phase transitionG2/mitotic-specific cyclin-B3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
response to hypoxiaCREB-binding proteinHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
chromatin remodelingCREB-binding proteinHomo sapiens (human)
regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
protein acetylationCREB-binding proteinHomo sapiens (human)
signal transductionCREB-binding proteinHomo sapiens (human)
canonical NF-kappaB signal transductionCREB-binding proteinHomo sapiens (human)
regulation of smoothened signaling pathwayCREB-binding proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase ICREB-binding proteinHomo sapiens (human)
N-terminal peptidyl-lysine acetylationCREB-binding proteinHomo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
protein destabilizationCREB-binding proteinHomo sapiens (human)
cellular response to nutrient levelsCREB-binding proteinHomo sapiens (human)
cellular response to UVCREB-binding proteinHomo sapiens (human)
homeostatic processCREB-binding proteinHomo sapiens (human)
embryonic digit morphogenesisCREB-binding proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
rhythmic processCREB-binding proteinHomo sapiens (human)
protein-containing complex assemblyCREB-binding proteinHomo sapiens (human)
regulation of cellular response to heatCREB-binding proteinHomo sapiens (human)
positive regulation of protein localization to nucleusCREB-binding proteinHomo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationCREB-binding proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAurora kinase BHomo sapiens (human)
mitotic cell cycleAurora kinase BHomo sapiens (human)
mitotic cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of B cell apoptotic processAurora kinase BHomo sapiens (human)
protein phosphorylationAurora kinase BHomo sapiens (human)
spindle organizationAurora kinase BHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
abscissionAurora kinase BHomo sapiens (human)
negative regulation of protein bindingAurora kinase BHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseAurora kinase BHomo sapiens (human)
negative regulation of cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of cytokinesisAurora kinase BHomo sapiens (human)
protein localization to kinetochoreAurora kinase BHomo sapiens (human)
cellular response to UVAurora kinase BHomo sapiens (human)
cleavage furrow formationAurora kinase BHomo sapiens (human)
post-translational protein modificationAurora kinase BHomo sapiens (human)
cell cycle G2/M phase transitionAurora kinase BHomo sapiens (human)
mitotic cytokinesis checkpoint signalingAurora kinase BHomo sapiens (human)
negative regulation of innate immune responseAurora kinase BHomo sapiens (human)
protein autophosphorylationAurora kinase BHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase BHomo sapiens (human)
positive regulation of telomerase activityAurora kinase BHomo sapiens (human)
regulation of chromosome segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointAurora kinase BHomo sapiens (human)
mitotic spindle assemblyAurora kinase BHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayAurora kinase BHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid separationAurora kinase BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
positive regulation of mitotic cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of telomere cappingAurora kinase BHomo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
mitotic spindle organizationAurora kinase BHomo sapiens (human)
regulation of cytokinesisAurora kinase BHomo sapiens (human)
proteolysisDipeptidyl peptidase 3Homo sapiens (human)
protein catabolic processDipeptidyl peptidase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (152)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingG2/mitotic-specific cyclin-B2Homo sapiens (human)
cadherin bindingG2/mitotic-specific cyclin-B2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activityG2/mitotic-specific cyclin-B2Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityCyclin-dependent kinase 1Homo sapiens (human)
chromatin bindingCyclin-dependent kinase 1Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 1Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 1Homo sapiens (human)
protein bindingCyclin-dependent kinase 1Homo sapiens (human)
ATP bindingCyclin-dependent kinase 1Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 1Homo sapiens (human)
kinase activityCyclin-dependent kinase 1Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 1Homo sapiens (human)
Hsp70 protein bindingCyclin-dependent kinase 1Homo sapiens (human)
histone kinase activityCyclin-dependent kinase 1Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 1Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 1Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
alpha-amylase activityAlpha-amylase 1A Homo sapiens (human)
calcium ion bindingAlpha-amylase 1A Homo sapiens (human)
chloride ion bindingAlpha-amylase 1A Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
transcription factor bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
manganese ion bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ribosomal small subunit bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
magnesium ion bindingPyruvate kinase PKMHomo sapiens (human)
RNA bindingPyruvate kinase PKMHomo sapiens (human)
mRNA bindingPyruvate kinase PKMHomo sapiens (human)
protein tyrosine kinase activityPyruvate kinase PKMHomo sapiens (human)
pyruvate kinase activityPyruvate kinase PKMHomo sapiens (human)
protein bindingPyruvate kinase PKMHomo sapiens (human)
ATP bindingPyruvate kinase PKMHomo sapiens (human)
MHC class II protein complex bindingPyruvate kinase PKMHomo sapiens (human)
potassium ion bindingPyruvate kinase PKMHomo sapiens (human)
cadherin bindingPyruvate kinase PKMHomo sapiens (human)
patched bindingG2/mitotic-specific cyclin-B1Homo sapiens (human)
protein bindingG2/mitotic-specific cyclin-B1Homo sapiens (human)
protein kinase bindingG2/mitotic-specific cyclin-B1Homo sapiens (human)
ubiquitin-like protein ligase bindingG2/mitotic-specific cyclin-B1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activator activityG2/mitotic-specific cyclin-B1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activityG2/mitotic-specific cyclin-B1Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin-epoxide hydrolase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
protein bindingCasein kinase II subunit alpha'Homo sapiens (human)
ATP bindingCasein kinase II subunit alpha'Homo sapiens (human)
protein serine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
histone kinase activityCyclin-dependent kinase 2Homo sapiens (human)
magnesium ion bindingCyclin-dependent kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein bindingCyclin-dependent kinase 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase 2Homo sapiens (human)
protein domain specific bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
17-beta-hydroxysteroid dehydrogenase (NADP+) activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase SYKHomo sapiens (human)
protein kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
protein serine/threonine kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase SYKHomo sapiens (human)
integrin bindingTyrosine-protein kinase SYKHomo sapiens (human)
protein bindingTyrosine-protein kinase SYKHomo sapiens (human)
ATP bindingTyrosine-protein kinase SYKHomo sapiens (human)
interleukin-15 receptor bindingTyrosine-protein kinase SYKHomo sapiens (human)
kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase SYKHomo sapiens (human)
phosphatase bindingTyrosine-protein kinase SYKHomo sapiens (human)
Toll-like receptor bindingTyrosine-protein kinase SYKHomo sapiens (human)
SH2 domain bindingTyrosine-protein kinase SYKHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase SYKHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase SYKHomo sapiens (human)
oxidoreductase activity1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
manganese ion binding1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
1-deoxy-D-xylulose-5-phosphate reductoisomerase activity1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
identical protein binding1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
metal ion binding1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
NADPH binding1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron ion bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein homodimerization activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
FAD bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein serine/threonine kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
signaling receptor bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
protease bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
p53 bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine/threonine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ubiquitin protein ligase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
dynactin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
NF-kappaB bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
protein bindingMitogen-activated protein kinase 10Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 10Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit betaHomo sapiens (human)
chromatin bindingCasein kinase II subunit betaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit betaHomo sapiens (human)
signaling receptor bindingCasein kinase II subunit betaHomo sapiens (human)
protein bindingCasein kinase II subunit betaHomo sapiens (human)
protein kinase regulator activityCasein kinase II subunit betaHomo sapiens (human)
protein domain specific bindingCasein kinase II subunit betaHomo sapiens (human)
protein-macromolecule adaptor activityCasein kinase II subunit betaHomo sapiens (human)
identical protein bindingCasein kinase II subunit betaHomo sapiens (human)
metal ion bindingCasein kinase II subunit betaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCasein kinase II subunit betaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
protein bindingCasein kinase II subunit alphaHomo sapiens (human)
ATP bindingCasein kinase II subunit alphaHomo sapiens (human)
kinase activityCasein kinase II subunit alphaHomo sapiens (human)
identical protein bindingCasein kinase II subunit alphaHomo sapiens (human)
Hsp90 protein bindingCasein kinase II subunit alphaHomo sapiens (human)
protein serine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 6Homo sapiens (human)
protein bindingCyclin-dependent kinase 6Homo sapiens (human)
ATP bindingCyclin-dependent kinase 6Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 6Homo sapiens (human)
FBXO family protein bindingCyclin-dependent kinase 6Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 6Homo sapiens (human)
microtubule bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
p53 bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
ErbB-2 class receptor bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
ATP bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
acetylcholine receptor activator activityCyclin-dependent-like kinase 5 Homo sapiens (human)
ErbB-3 class receptor bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
tau protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
tau-protein kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
Hsp90 protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein serine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
lactoylglutathione lyase activityLactoylglutathione lyaseHomo sapiens (human)
protein bindingLactoylglutathione lyaseHomo sapiens (human)
zinc ion bindingLactoylglutathione lyaseHomo sapiens (human)
protease bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
calcium ion bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
protein bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
kinase activityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
protein kinase bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
protein kinase activator activityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
ionotropic glutamate receptor bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
alpha-tubulin bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
protein serine/threonine kinase activator activityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
cadherin bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
ephrin receptor bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
beta-tubulin bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
actin filament bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activator activityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 14Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 14Homo sapiens (human)
mitogen-activated protein kinase p38 bindingMitogen-activated protein kinase 14Homo sapiens (human)
NFAT protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alpha 3Homo sapiens (human)
protein bindingCasein kinase II subunit alpha 3Homo sapiens (human)
ATP bindingCasein kinase II subunit alpha 3Homo sapiens (human)
protein serine kinase activityCasein kinase II subunit alpha 3Homo sapiens (human)
protein bindingG2/mitotic-specific cyclin-B3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activityG2/mitotic-specific cyclin-B3Homo sapiens (human)
transcription coactivator bindingCREB-binding proteinHomo sapiens (human)
p53 bindingCREB-binding proteinHomo sapiens (human)
chromatin bindingCREB-binding proteinHomo sapiens (human)
damaged DNA bindingCREB-binding proteinHomo sapiens (human)
transcription coactivator activityCREB-binding proteinHomo sapiens (human)
transcription corepressor activityCREB-binding proteinHomo sapiens (human)
histone acetyltransferase activityCREB-binding proteinHomo sapiens (human)
protein bindingCREB-binding proteinHomo sapiens (human)
zinc ion bindingCREB-binding proteinHomo sapiens (human)
acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
MRF bindingCREB-binding proteinHomo sapiens (human)
histone H3K18 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
histone H3K27 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
peptide-lysine-N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide lactyltransferase activityCREB-binding proteinHomo sapiens (human)
DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
chromatin DNA bindingCREB-binding proteinHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase BHomo sapiens (human)
protein bindingAurora kinase BHomo sapiens (human)
ATP bindingAurora kinase BHomo sapiens (human)
kinase bindingAurora kinase BHomo sapiens (human)
protein serine kinase activityAurora kinase BHomo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 3Homo sapiens (human)
protein bindingDipeptidyl peptidase 3Homo sapiens (human)
metalloexopeptidase activityDipeptidyl peptidase 3Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 3Homo sapiens (human)
zinc ion bindingDipeptidyl peptidase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (131)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
centrosomeG2/mitotic-specific cyclin-B2Homo sapiens (human)
cytosolG2/mitotic-specific cyclin-B2Homo sapiens (human)
microtubule cytoskeletonG2/mitotic-specific cyclin-B2Homo sapiens (human)
membraneG2/mitotic-specific cyclin-B2Homo sapiens (human)
centrosomeG2/mitotic-specific cyclin-B2Homo sapiens (human)
cytoplasmG2/mitotic-specific cyclin-B2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexG2/mitotic-specific cyclin-B2Homo sapiens (human)
nucleusG2/mitotic-specific cyclin-B2Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
mitochondrial matrixCyclin-dependent kinase 1Homo sapiens (human)
chromosome, telomeric regionCyclin-dependent kinase 1Homo sapiens (human)
nucleusCyclin-dependent kinase 1Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 1Homo sapiens (human)
mitochondrionCyclin-dependent kinase 1Homo sapiens (human)
endoplasmic reticulum membraneCyclin-dependent kinase 1Homo sapiens (human)
centrosomeCyclin-dependent kinase 1Homo sapiens (human)
cytosolCyclin-dependent kinase 1Homo sapiens (human)
spindle microtubuleCyclin-dependent kinase 1Homo sapiens (human)
membraneCyclin-dependent kinase 1Homo sapiens (human)
midbodyCyclin-dependent kinase 1Homo sapiens (human)
extracellular exosomeCyclin-dependent kinase 1Homo sapiens (human)
mitotic spindleCyclin-dependent kinase 1Homo sapiens (human)
cyclin A1-CDK1 complexCyclin-dependent kinase 1Homo sapiens (human)
cyclin A2-CDK1 complexCyclin-dependent kinase 1Homo sapiens (human)
cyclin B1-CDK1 complexCyclin-dependent kinase 1Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 1Homo sapiens (human)
cytoplasmCyclin-dependent kinase 1Homo sapiens (human)
nucleusCyclin-dependent kinase 1Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular spaceAlpha-amylase 1A Homo sapiens (human)
extracellular exosomeAlpha-amylase 1A Homo sapiens (human)
extracellular spaceAlpha-amylase 1A Homo sapiens (human)
nucleusSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleolusSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytosolSerine/threonine-protein kinase pim-1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
extracellular regionPyruvate kinase PKMHomo sapiens (human)
nucleusPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
mitochondrionPyruvate kinase PKMHomo sapiens (human)
rough endoplasmic reticulumPyruvate kinase PKMHomo sapiens (human)
cytosolPyruvate kinase PKMHomo sapiens (human)
ciliumPyruvate kinase PKMHomo sapiens (human)
vesiclePyruvate kinase PKMHomo sapiens (human)
secretory granule lumenPyruvate kinase PKMHomo sapiens (human)
collagen-containing extracellular matrixPyruvate kinase PKMHomo sapiens (human)
extracellular exosomePyruvate kinase PKMHomo sapiens (human)
extracellular vesiclePyruvate kinase PKMHomo sapiens (human)
ficolin-1-rich granule lumenPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
mitochondrial matrixG2/mitotic-specific cyclin-B1Homo sapiens (human)
spindle poleG2/mitotic-specific cyclin-B1Homo sapiens (human)
nucleusG2/mitotic-specific cyclin-B1Homo sapiens (human)
nucleoplasmG2/mitotic-specific cyclin-B1Homo sapiens (human)
cytoplasmG2/mitotic-specific cyclin-B1Homo sapiens (human)
centrosomeG2/mitotic-specific cyclin-B1Homo sapiens (human)
cytosolG2/mitotic-specific cyclin-B1Homo sapiens (human)
membraneG2/mitotic-specific cyclin-B1Homo sapiens (human)
cyclin B1-CDK1 complexG2/mitotic-specific cyclin-B1Homo sapiens (human)
outer kinetochoreG2/mitotic-specific cyclin-B1Homo sapiens (human)
cytoplasmG2/mitotic-specific cyclin-B1Homo sapiens (human)
nucleusG2/mitotic-specific cyclin-B1Homo sapiens (human)
centrosomeG2/mitotic-specific cyclin-B1Homo sapiens (human)
lipid dropletPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmic side of plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolGlycogen synthase kinase-3 betaRattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
PcG protein complexCasein kinase II subunit alpha'Homo sapiens (human)
acrosomal vesicleCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
nucleoplasmCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alpha'Homo sapiens (human)
chromatinCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
chromosome, telomeric regionCyclin-dependent kinase 2Homo sapiens (human)
condensed chromosomeCyclin-dependent kinase 2Homo sapiens (human)
X chromosomeCyclin-dependent kinase 2Homo sapiens (human)
Y chromosomeCyclin-dependent kinase 2Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
nuclear envelopeCyclin-dependent kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
endosomeCyclin-dependent kinase 2Homo sapiens (human)
centrosomeCyclin-dependent kinase 2Homo sapiens (human)
cytosolCyclin-dependent kinase 2Homo sapiens (human)
Cajal bodyCyclin-dependent kinase 2Homo sapiens (human)
cyclin A1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 2Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
endoplasmic reticulumTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
endoplasmic reticulum membraneTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
intracellular membrane-bounded organelleTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
endoplasmic reticulumTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
cytoplasmTyrosine-protein kinase SYKHomo sapiens (human)
nucleusTyrosine-protein kinase SYKHomo sapiens (human)
cytoplasmTyrosine-protein kinase SYKHomo sapiens (human)
cytosolTyrosine-protein kinase SYKHomo sapiens (human)
plasma membraneTyrosine-protein kinase SYKHomo sapiens (human)
early phagosomeTyrosine-protein kinase SYKHomo sapiens (human)
B cell receptor complexTyrosine-protein kinase SYKHomo sapiens (human)
protein-containing complexTyrosine-protein kinase SYKHomo sapiens (human)
T cell receptor complexTyrosine-protein kinase SYKHomo sapiens (human)
plasma membraneTyrosine-protein kinase SYKHomo sapiens (human)
Dxr protein complex1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
peroxisomeXanthine dehydrogenase/oxidaseHomo sapiens (human)
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
sarcoplasmic reticulumXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
mitochondrionGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 alphaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 alphaHomo sapiens (human)
neuronal cell bodyGlycogen synthase kinase-3 alphaHomo sapiens (human)
apical dendriteGlycogen synthase kinase-3 alphaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 alphaHomo sapiens (human)
proximal dendriteGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 alphaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 alphaHomo sapiens (human)
axonGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 alphaHomo sapiens (human)
glutamatergic synapseGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrionGlycogen synthase kinase-3 betaHomo sapiens (human)
centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
plasma membraneGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
dendriteGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 betaHomo sapiens (human)
presynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
Wnt signalosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleoplasmMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 10Homo sapiens (human)
cytosolMitogen-activated protein kinase 10Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 10Homo sapiens (human)
nucleusMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneCasein kinase II subunit betaHomo sapiens (human)
PcG protein complexCasein kinase II subunit betaHomo sapiens (human)
PML bodyCasein kinase II subunit betaHomo sapiens (human)
extracellular regionCasein kinase II subunit betaHomo sapiens (human)
nucleusCasein kinase II subunit betaHomo sapiens (human)
nucleoplasmCasein kinase II subunit betaHomo sapiens (human)
cytoplasmCasein kinase II subunit betaHomo sapiens (human)
cytosolCasein kinase II subunit betaHomo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit betaHomo sapiens (human)
secretory granule lumenCasein kinase II subunit betaHomo sapiens (human)
extracellular exosomeCasein kinase II subunit betaHomo sapiens (human)
ficolin-1-rich granule lumenCasein kinase II subunit betaHomo sapiens (human)
chromatinCasein kinase II subunit betaHomo sapiens (human)
cytoplasmCasein kinase II subunit betaHomo sapiens (human)
PcG protein complexCasein kinase II subunit alphaHomo sapiens (human)
PML bodyCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleoplasmCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
plasma membraneCasein kinase II subunit alphaHomo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alphaHomo sapiens (human)
Sin3-type complexCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
ruffleCyclin-dependent kinase 6Homo sapiens (human)
nucleusCyclin-dependent kinase 6Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 6Homo sapiens (human)
cytoplasmCyclin-dependent kinase 6Homo sapiens (human)
centrosomeCyclin-dependent kinase 6Homo sapiens (human)
cytosolCyclin-dependent kinase 6Homo sapiens (human)
cyclin D1-CDK6 complexCyclin-dependent kinase 6Homo sapiens (human)
cyclin D3-CDK6 complexCyclin-dependent kinase 6Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 6Homo sapiens (human)
cyclin D2-CDK6 complexCyclin-dependent kinase 6Homo sapiens (human)
cytoplasmCyclin-dependent kinase 6Homo sapiens (human)
nucleusCyclin-dependent kinase 6Homo sapiens (human)
microtubuleCyclin-dependent-like kinase 5 Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
cytoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
cytosolCyclin-dependent-like kinase 5 Homo sapiens (human)
plasma membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
postsynaptic densityCyclin-dependent-like kinase 5 Homo sapiens (human)
membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
protein kinase 5 complexCyclin-dependent-like kinase 5 Homo sapiens (human)
lamellipodiumCyclin-dependent-like kinase 5 Homo sapiens (human)
cell junctionCyclin-dependent-like kinase 5 Homo sapiens (human)
filopodiumCyclin-dependent-like kinase 5 Homo sapiens (human)
axonCyclin-dependent-like kinase 5 Homo sapiens (human)
dendriteCyclin-dependent-like kinase 5 Homo sapiens (human)
growth coneCyclin-dependent-like kinase 5 Homo sapiens (human)
neuromuscular junctionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron projectionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuronal cell bodyCyclin-dependent-like kinase 5 Homo sapiens (human)
perikaryonCyclin-dependent-like kinase 5 Homo sapiens (human)
presynapseCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
cytoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleoplasmLactoylglutathione lyaseHomo sapiens (human)
cytoplasmLactoylglutathione lyaseHomo sapiens (human)
cytosolLactoylglutathione lyaseHomo sapiens (human)
plasma membraneLactoylglutathione lyaseHomo sapiens (human)
extracellular exosomeLactoylglutathione lyaseHomo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 5 activator 1Homo sapiens (human)
nucleusCyclin-dependent kinase 5 activator 1Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 5 activator 1Homo sapiens (human)
cytoplasmCyclin-dependent kinase 5 activator 1Homo sapiens (human)
cytosolCyclin-dependent kinase 5 activator 1Homo sapiens (human)
plasma membraneCyclin-dependent kinase 5 activator 1Homo sapiens (human)
postsynaptic densityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
membraneCyclin-dependent kinase 5 activator 1Homo sapiens (human)
protein kinase 5 complexCyclin-dependent kinase 5 activator 1Homo sapiens (human)
axonCyclin-dependent kinase 5 activator 1Homo sapiens (human)
dendriteCyclin-dependent kinase 5 activator 1Homo sapiens (human)
growth coneCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuromuscular junctionCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuron projectionCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuronal cell bodyCyclin-dependent kinase 5 activator 1Homo sapiens (human)
dendritic spineCyclin-dependent kinase 5 activator 1Homo sapiens (human)
perikaryonCyclin-dependent kinase 5 activator 1Homo sapiens (human)
intracellular membrane-bounded organelleCyclin-dependent kinase 5 activator 1Homo sapiens (human)
contractile muscle fiberCyclin-dependent kinase 5 activator 1Homo sapiens (human)
perinuclear region of cytoplasmCyclin-dependent kinase 5 activator 1Homo sapiens (human)
presynapseCyclin-dependent kinase 5 activator 1Homo sapiens (human)
cytoplasmCyclin-dependent kinase 5 activator 1Homo sapiens (human)
growth coneCyclin-dependent kinase 5 activator 1Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
spindle poleMitogen-activated protein kinase 14Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 14Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 14Homo sapiens (human)
secretory granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 14Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmCasein kinase II subunit alpha 3Homo sapiens (human)
nucleusCasein kinase II subunit alpha 3Homo sapiens (human)
cytosolCasein kinase II subunit alpha 3Homo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alpha 3Homo sapiens (human)
nuclear speckG2/mitotic-specific cyclin-B3Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexG2/mitotic-specific cyclin-B3Homo sapiens (human)
cytoplasmG2/mitotic-specific cyclin-B3Homo sapiens (human)
nucleusG2/mitotic-specific cyclin-B3Homo sapiens (human)
centrosomeG2/mitotic-specific cyclin-B3Homo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
nucleusCREB-binding proteinHomo sapiens (human)
nucleoplasmCREB-binding proteinHomo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
cytosolCREB-binding proteinHomo sapiens (human)
nuclear bodyCREB-binding proteinHomo sapiens (human)
chromatinCREB-binding proteinHomo sapiens (human)
histone acetyltransferase complexCREB-binding proteinHomo sapiens (human)
transcription regulator complexCREB-binding proteinHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
condensed chromosome, centromeric regionAurora kinase BHomo sapiens (human)
nucleusAurora kinase BHomo sapiens (human)
nucleoplasmAurora kinase BHomo sapiens (human)
spindleAurora kinase BHomo sapiens (human)
cytosolAurora kinase BHomo sapiens (human)
chromocenterAurora kinase BHomo sapiens (human)
microtubule cytoskeletonAurora kinase BHomo sapiens (human)
midbodyAurora kinase BHomo sapiens (human)
chromosome passenger complexAurora kinase BHomo sapiens (human)
mitotic spindle poleAurora kinase BHomo sapiens (human)
mitotic spindle midzoneAurora kinase BHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
spindle pole centrosomeAurora kinase BHomo sapiens (human)
spindle microtubuleAurora kinase BHomo sapiens (human)
spindle midzoneAurora kinase BHomo sapiens (human)
cytosolDipeptidyl peptidase 3Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 3Homo sapiens (human)
cytoplasmDipeptidyl peptidase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (417)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347356HPAF-II 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347352COV-362 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347393qHTS for inhibitors of ER calcium dysfunction: SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347351U-118MG Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID134737610-beta competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347361HEK293 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347392qHTS for activators of dead-cell proteases activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347380qHTS for Antimalaria activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347396qHTS for inhibitors of Wild type Zika virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347368G06 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347371J3T Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347390Secretion counterscreen for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347360HPAF-II 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347377DH5-alpha competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347372qHTS for Constitutive Androstane Receptor (CAR) Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347362Diaphorse counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347373qHTS for Constitutive Androstane Receptor (CAR) Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347389qHTS assay for small molecule disruptors of mitochondrial membrane potential screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347402qHTS for inhibitors of Rabies Virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347349Panc-1005 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347369MCF7 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347367qHTS for ATAD5 Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347401Redox Reaction Profiling qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347375qHTS for Hypoxia signaling pathway (HIF-1) agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347366KB-3-1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347359HEK293 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347358HPAF-II 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347364KB-8-5-11 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347400Viability qHTS for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347379qHTS for Inflammasome Signaling Inhibitors: IL-1-beta AlphaLISA screen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347394Vero-766 cells viability qHTS against the NCATS CANVASS Library: Counterscreen for Zika virus inhibition assay2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347357HEK293 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347381Inflammasome Signaling qHTS Counterscreen: IL-1-beta AlphaLISA counterscreen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347347UWB1.289 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347345OV-KATE Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347346HPAF-II Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347353A2780 Cisplatin Sensitive Ovarian Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347391qHTS for activators of Nrf2/ARE signaling pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347374qHTS for Hypoxia signaling pathway (HIF-1) antagonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347350SW1088 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347365SDT Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347354UWB1.289-WTBRCA1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347363Firefly luciferase counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347355HEK-293 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347370qHTS for ATAD5 Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347388qHTS for Activators of p53 Stress Response Pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347348OV-SAHO Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347378qHTS for H2AX Agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347387Cytotoxicity qHTS for assessment of Hepg2 cells membrane integrity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID681202TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 uM, Fisetin: 50 uM) in BCRP-expressing MCF-7 cells2004Molecular pharmacology, May, Volume: 65, Issue:5
Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
AID646591Antiinflammatory activity in mouse N9 cells assessed as reduction of LPS-induced microglial activation at 1 to 10 uM measured as nitrite level after 24 hrs by Griess reagent-based assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
AID397982Inhibition of JNK activation in mouse HT22 cells at 10 uM treated simultaneously with iodoacetic acid for 2 hrs followed by 2 hrs of recovery in presence of drug alone by immunoblot analysis2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity.
AID1464282Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay2017Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20
Natural neuro-inflammatory inhibitors from Caragana turfanensis.
AID646595Induction of Nrf2 expression in mouse HT22 cells from 1 to 4 hrs by immunoblotting2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
AID1879128Antibacterial activity in BALB/c mouse infected with NDM-1 positive Escherichia coli ZJ487 assessed as mouse death rate at 50 mg/kg, sc administered every 12 hrs and measured after 96 hrs post infection2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID309798Inhibition of 12-hLO2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID1744550Inhibition of cytochrome c (unknown origin) assessed as reduction reduction of cyt c from its ferric state to ferrous state incubated for 20 mins in presence of cardiolipin by UV-vis Spectrophotometric assay2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID1516849Antifungal activity against Candida krusei 168 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID397981Inhibition of p38 MAPK activation in mouse HT22 cells at 10 uM treated simultaneously with iodoacetic acid for 2 hrs followed by 2 hrs of recovery in presence of drug alone by immunoblot analysis2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity.
AID1879111Synergistic antibacterial activity in BALB/c mouse infected with NDM-1 positive Escherichia coli ZJ487 assessed as increase in survival rate at 50 mg/kg, sc administered every 12 hrs and measured after 96 hrs post infection in presence of meropenem2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879088Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of cefotaxime by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1464283Cytotoxicity against mouse BV2 cells assessed as reduction in cell viability at 1 to 100 uM after 24 hrs in presence of LPS by MTT assay2017Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20
Natural neuro-inflammatory inhibitors from Caragana turfanensis.
AID1879032Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as doxycycline MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879070Synergistic antibacterial activity against pET28a NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of ampicillin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879053Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as kanamycin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879073Synergistic antibacterial activity against pET28a NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of florfenicol by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID338025Inhibition of rat liver mitochondrial ATPase assessed per mg of protein
AID1879116Binding affinity to NDM-1 V73A mutant (unknown origin) assessed as binding free energy by fluorescence quenching method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID332647Enhancement of human DNA topoisomerase 2-mediated Escherichia coli pUC8 DNA cleavage after 30 mins by agarose gel electrophoresis1995Journal of natural products, Feb, Volume: 58, Issue:2
Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships.
AID1572647Inhibition of PKC in rat brain homogenate at 50 uM using FKKSFKL-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins in presence of [gamma-32P]ATP by liquid scintillation counting analysis relative to control2019Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5
A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.
AID1631845Cytotoxicity against human A549 cells at 100 uM after 48 hrs by cell titer glo assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID338028Inhibition of beef heart mitochondrial succinoxidase assessed per mg of protein
AID1879036Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as meropenem MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879098Synergistic antibacterial activity against NDM-1 negative Escherichia coli BL21(DE3) (pET28a) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of meropenem by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1744547Inhibition of cytochrome c (unknown origin) assessed as reduction in cyt c-CL complex formation at 10 uM incubated for 15 mins in presence of cardiolipin by Trp-59 fluorescence assay relative to control2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID1127223Binding affinity DPPC multilamellar vesicles assessed as chemical shift at 1:5 compound/lipid ratio at 333 K by nuclear magnetic resonance analysis2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID1631837Inhibition of Trypanosoma brucei PTR1 at 50 uM using H2B as substrate incubated for 10 mins followed by addition of NADPH measured for 10 to 50 mins2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1127213Binding affinity DPPC multilamellar vesicles assessed as main transition temperature at 1:10 compound/lipid ratio after 2 hrs by differential scanning calorimetry method (Rvb = 41.98 degC)2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID1516850Antifungal activity against Candida albicans 501 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID404013In vivo antitumor activity against mouse P388 cells
AID1879046Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as streptomycin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID338023Inhibition of beef heart mitochondrial NADH oxidase assessed as specific activity at 0.35 mM preincubated for 15 mins relative to control
AID400608Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs1996Journal of natural products, Mar, Volume: 59, Issue:3
Ability of different flavonoids to inhibit the procoagulant activity of adherent human monocytes.
AID429128Agonist activity at androgen receptor in human MDA-kb2 cells assessed as stimulation of luciferase activity at 100 uM by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.
AID1879097Synergistic antibacterial activity against NDM-1 positive MCR1 carrying Escherichia coli ZJ487 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of meropenem by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1364959Antiviral activity against Chikungunya virus MY/065/08/FN295485 infected in African green monkey Vero cells assessed as reduction in virus yield after 48 hrs by titration assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID339057Inhibition of Moloney murine leukemia virus reverse transcriptase using (ribocytidylic acid)n(deoxyguanylic acid)12-18 as template primer by liquid scintillation counting1992Journal of natural products, Feb, Volume: 55, Issue:2
Inhibitory effects of flavonoids on Moloney murine leukemia virus reverse transcriptase activity.
AID1744549Inhibition of cytochrome c (unknown origin) assessed as reduction reduction of cyt c from its ferric state to ferrous state at 10 uM incubated for 20 mins in presence of cardiolipin by UV-vis Spectrophotometric assay relative to control2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID1879123Inhibition of NDM-1 activity (unknown origin) in presence of zinc ion2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879104Inhibition of metallo-beta-lactamase NDM-9 (unknown origin) using nitrocefin as substrate preincubated for 15 min followed by substrate addition and measured after 15 min by microplate reader assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1408297Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship and pharmacokinetic studies of 3-O-substitutedflavonols as anti-prostate cancer agents.
AID404008Cytotoxicity against human KB cells
AID596673Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 30 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID180466Inhibitory effect on the oxidative degradation of membrane lipids (lipid peroxidation assay) in microsomes of rat.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Synthesis of novel 3,7-substituted-2-(3',4'-dihydroxyphenyl)flavones with improved antioxidant activity.
AID404067In vivo antitumor activity against mouse S180 cells
AID1879085Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of tetracycline by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID257080Inhibitory activity against PIM1 at 10 uM2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
AID1408298Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship and pharmacokinetic studies of 3-O-substitutedflavonols as anti-prostate cancer agents.
AID338027Inhibition of beef heart mitochondrial NADH oxidase assessed per mg of protein
AID397985Activation of ERK phosphorylation in mouse HT22 cells at 10 uM treated simultaneously with iodoacetic acid for 2 hrs followed by 2 hrs of recovery in presence of drug alone by immunoblot analysis2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity.
AID658254Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication at 50 uM after 72 hrs by EGFP assay2012European journal of medicinal chemistry, Jun, Volume: 52Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy.
AID399341Antioxidant activity assessed as superoxide-scavenging activity by nitrite method1998Journal of natural products, Jan, Volume: 61, Issue:1
Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers.
AID1879093Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of imipenem by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID429129Agonist activity at glucocorticoid receptor in human MDA-kb2 cells assessed as stimulation of luciferase activity at 100 uM by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.
AID397976Neuroprotective effect against glutamate-induced neuronal cell death in mouse HT22 cells assessed as cell survival at 1 to 10 uM treated simultaneously with glutamate after 24 hrs by MTT assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity.
AID1516856Antifungal activity against Candida glabrata 587 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1879113Inhibition of class C metallo-beta-lactamase AmpC (unknown origin) up to 64 ug/ml using nitrocefin as substrate preincubated for 15 min followed by substrate addition and measured after 15 min by microplate reader assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1832962Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced IL6 secretion at 10 uM incubated for 2 followed by LPS stimulation and measured after 22 hrs by ELISA relative to control2021Bioorganic & medicinal chemistry, 11-01, Volume: 49Design, synthesis and bioactivity evaluation of fisetin derivatives as potential anti-inflammatory agents against LPS-induced acute lung injury.
AID1631842Inhibition of human thymidylate synthase at 50 uM using folic aid as substrate by spectrophotometric analysis2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1896737Anti-ferroptotic activity against erastin-induced ferroptosis in human HaCaT cells assessed as cell viability at 5 uM pretreated with compound for 4 hrs followed by erastin challenge for 24 hrs by MTT assay (Rvb = 45%)2022Bioorganic & medicinal chemistry, Nov-05, Volume: 75Phenolic furanochromene hydrazone derivatives: Synthesis, antioxidant activity, ferroptosis inhibition, DNA cleavage and DNA molecular docking studies.
AID1434689Inhibition of sucrose loaded POPC/POPE/POPS/PtdIns(3,4,5)P3 (59:20:20:1) liposome binding to eGFP-fused PDK1 PH domain (unknown origin) expressed in Escherichia coli BL21 at 10 uM after 10 mins by fluorescence spectrophotometry based pull down assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Inhibitory potential of flavonoids on PtdIns(3,4,5)P3 binding with the phosphoinositide-dependent kinase 1 pleckstrin homology domain.
AID1364960Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Chikungunya virus MY/065/08/FN2954852017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1879051Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as meropenem MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879062Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as imipenem MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1127215Binding affinity DPPC multilamellar vesicles after 2 hrs by centrifugation method2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID1879126Inhibition of NDM-1 H250A mutant activity (unknown origin) in presence of zinc ion2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID671213Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID1130099Inhibition of human aromatase using androstenedione as substrate assessed as remaining estrone level at 10 uM after 30 mins by LC-MS/MS analysis relative to control2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Inhibitory effect of Rhus verniciflua Stokes extract on human aromatase activity; butin is its major bioactive component.
AID338024Inhibition of beef heart mitochondrial succinoxidase assessed as specific activity at 0.35 mM preincubated for 15 mins relative to control
AID1879057Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as cefotaxime MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID232853Antioxidant activity was determined using trolox equivalent antioxidant capacity assay.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Synthesis of novel 3,7-substituted-2-(3',4'-dihydroxyphenyl)flavones with improved antioxidant activity.
AID397980Effect on total intracellular glutathione level in mouse HT22 cells in presence of iodoacetic acid2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID701071Inhibition of SYK2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Discovery and development of spleen tyrosine kinase (SYK) inhibitors.
AID1879099Synergistic antibacterial activity against NDM-1 negative Escherichia coli ATCC25922 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of meropenem by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID265761Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF542006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID1879033Antibacterial activity against NDM-1 positive MCR1 carrying Escherichia coli ZJ487 isolates assessed as meropenem MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID404012In vivo antitumor activity against mouse LLC cells
AID317345Cytotoxicity against human MDA-MB-435 cells at 10 uM after 96 hrs by MTT assay2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
The effect of flavonoid derivatives on doxorubicin transport and metabolism.
AID1879121Binding affinity to NDM-1 M248A mutant (unknown origin) assessed as binding constant by fluorescence quenching method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879064Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as colistin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID293299Antioxidant activity in BALB/c mouse BM cells assessed as inhibition of ROS production2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID1879065Antibacterial activity against NDM-1 negative Escherichia coli BL21(DE3) (pET28a) isolates assessed as meropenem MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID441663Cytotoxicity against human THP1 cells after 24 hrs by MTS assay2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase.
AID379055Cytotoxicity against human monocytes assessed as depletion of cellular LDH activity1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID1879037Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as ampicillin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID265760Inhibition of FabG2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID1879092Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of streptomycin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879095Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of rifampicin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID358174Inhibition of p56 lck1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1879063Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as rifampicin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879094Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of doxycycline by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID309802Reductive inhibition of 15-hLO12007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID1127225Antiproliferative activity against human K562 cells assessed as cell growth at 10'-4 ug/ml after 48 hrs by SRB assay relative to control2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID1879082Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of meropenem by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1127216Binding affinity DPPC multilamellar vesicles assessed as pre-transition temperature at 1:20 compound/lipid ratio after 2 hrs by differential scanning calorimetry method (Rvb = 34.10 degC)2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID265762Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K12006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID336952Inhibition of bovine thymocytes protein tyrosine kinase assessed as angiotensin 1 phosphorylation
AID1516899Antifungal activity against Cryptococcus gattii after 72 hrs2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1190379Antiviral activity against dengue virus 2 infected in african green monkey Vero cells assessed as reduction in viral replication dosed after adsorption with 200 FFU of virus for 1 hour by foci forming unit reduction assay2015Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3
Flavonoids as noncompetitive inhibitors of Dengue virus NS2B-NS3 protease: inhibition kinetics and docking studies.
AID1631846Cytotoxicity against human WI38 cells at 100 uM after 48 hrs by cell titer glo assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID357255Antifungal activity against Cryptococcus neoformans ATCC 901132002Journal of natural products, Dec, Volume: 65, Issue:12
Fatty acid synthase inhibitors from plants: isolation, structure elucidation, and SAR studies.
AID1879125Inhibition of NDM-1 M248A mutant activity (unknown origin) in presence of zinc ion2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879105Synergistic antibacterial activity against Escherichia coli ZC-YN3 assessed as bacterial death at 32 ug/ml measured within 3 hrs in presence of meropenem by time kill assay curve based analysis2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879112Synergistic antibacterial activity in BALB/c mouse infected with NDM-1 positive Escherichia coli ZJ487 assessed as reduction in bacterial load in thigh muscle at 50 mg/kg, sc administered every 12 hrs and measured after 72 hrs post infection in presence o2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879089Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of ciprofloxacin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1516858Antifungal activity against Candida glabrata 493 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID456319ABTS radical scavenging activity assessed as vitamin C equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID1631840Inhibition of Trypanosoma brucei DHFR at 50 uM using folic aid as substrate by spectrophotometric analysis2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1408296Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship and pharmacokinetic studies of 3-O-substitutedflavonols as anti-prostate cancer agents.
AID1539764Inhibition of CK2alpha (unknown origin)2019European journal of medicinal chemistry, Nov-01, Volume: 181Small molecule modulators targeting protein kinase CK1 and CK2.
AID1879091Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of lincomycin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1631847Inhibition of recombinant full-length human aurora B kinase expressed in baculovirus system using MBP as substrate at 10 uM incubated for 45 mins by ADP-glo kinase assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID397974Neuroprotective effect against iodoacetic acid-induced ischemia in mouse HT22 cells assessed as cell survival at 1 to 10 uM treated simultaneously with iodoacetic acid for 2 hrs followed by incubation in fresh medium containing drug alone for 20 hrs measu2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity.
AID1294141Inhibition of CK2 (unknown origin)2016European journal of medicinal chemistry, Jun-10, Volume: 115Design and synthesis of novel protein kinase CK2 inhibitors on the base of 4-aminothieno[2,3-d]pyrimidines.
AID1264950Cytotoxicity against human MSC assessed as cell viability at 1 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1516857Antifungal activity against Candida glabrata 510 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID332929Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay1994Journal of natural products, Jan, Volume: 57, Issue:1
Anti-AIDS agents, 10. Acacetin-7-O-beta-D-galactopyranoside, an anti-HIV principle from Chrysanthemum morifolium and a structure-activity correlation with some related flavonoids.
AID1832963Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability at 10 uM after 24 hrs by MTT assay2021Bioorganic & medicinal chemistry, 11-01, Volume: 49Design, synthesis and bioactivity evaluation of fisetin derivatives as potential anti-inflammatory agents against LPS-induced acute lung injury.
AID309799Inhibition of 15-hLO12007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID357253Inhibition of Saccharomyces cerevisiae fatty acid synthase2002Journal of natural products, Dec, Volume: 65, Issue:12
Fatty acid synthase inhibitors from plants: isolation, structure elucidation, and SAR studies.
AID293298Antioxidant activity assessed as inhibition of superoxide production by xanthine/xanthine oxidase method2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID658255Cytotoxicity against human Huh7.5.1 cells by MTT assay2012European journal of medicinal chemistry, Jun, Volume: 52Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy.
AID1434691Inhibition of sucrose loaded POPC/POPE/POPS/PtdIns(3,4,5)P3 (59:20:20:1) liposome binding to eGFP-fused PDK1 PH domain (unknown origin) expressed in Escherichia coli BL21 after 10 mins by fluorescence spectrophotometry based pull down assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Inhibitory potential of flavonoids on PtdIns(3,4,5)P3 binding with the phosphoinositide-dependent kinase 1 pleckstrin homology domain.
AID1264957Cytotoxicity against human MSC assessed as cell viability at 5 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID93508IC50 was measured as concentration required to inhibit 50% of HIV-integrase integration1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1516851Antifungal activity against Candida albicans 498 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1879081Synergistic antibacterial activity against pET28a NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of colistin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1631844Mitochondrial toxicity in human 786-O cells incubated for 6 hrs by mitotracker red staining based-uptake method2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1879042Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as cefotaxime MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID404692Inhibition of human salivary alpha-amylase2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Flavonoids for controlling starch digestion: structural requirements for inhibiting human alpha-amylase.
AID332930Cytotoxicity against human H9 cells after 3 days1994Journal of natural products, Jan, Volume: 57, Issue:1
Anti-AIDS agents, 10. Acacetin-7-O-beta-D-galactopyranoside, an anti-HIV principle from Chrysanthemum morifolium and a structure-activity correlation with some related flavonoids.
AID1879110Antibacterial activity in BALB/c mouse infected with NDM-1 positive Escherichia coli ZJ487 assessed as increase in survival rate at 10 mg/kg, sc administered every 12 hrs and measured after 96 hrs post infection2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID441659Inhibition of human plasma BChE by Ellman's method2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase.
AID1434690Inhibition of sucrose loaded POPC/POPE/POPS/PtdIns(3,4,5)P3 (59:20:20:1) liposome binding to eGFP-fused PDK1 PH domain (unknown origin) expressed in Escherichia coli BL21 at 20 uM after 10 mins by fluorescence spectrophotometry based pull down assay relat2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Inhibitory potential of flavonoids on PtdIns(3,4,5)P3 binding with the phosphoinositide-dependent kinase 1 pleckstrin homology domain.
AID596670Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 1 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID240981Inhibition of glycogen synthase kinase 32005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.
AID1744548Inhibition of cytochrome c (unknown origin) assessed as reduction in cyt c-CL peroxidase activity at 10 uM up to 20 mins in presence of cardiolipin by Amplex red staining based fluorescence assay relative to control2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID444614Inhibition of Trypanosoma cruzi cruzain by quantitative high throughput screening2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease.
AID1516855Antifungal activity against Candida glabrata 531 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1879124Inhibition of NDM-1 V73A mutant activity (unknown origin) in presence of zinc ion2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1879066Antibacterial activity against NDM-1 negative Escherichia coli ATCC25922 isolates assessed as meropenem MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1881916Inhibition of recombinant PKM2 (unknown origin) Gly128, Asp177, Asp178, Ser362, Hie78, Be51, Asn75 residues2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID1879096Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of colistin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879048Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as doxycycline MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID309801Inhibition of 15-hLO22007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID293297Antioxidant activity assessed as DPPH radical scavenging activity after 20 min2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID671220Inhibition of prostate specific antigen expression in human 22Rv1 cells assessed as PSA protein level at 20 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID596671Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 3 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1879047Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as imipenem MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879103Inhibition of metallo-beta-lactamase IMP-1 (unknown origin) using nitrocefin as substrate preincubated for 15 min followed by substrate addition and measured after 15 min by microplate reader assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID332931Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV1 3B1994Journal of natural products, Jan, Volume: 57, Issue:1
Anti-AIDS agents, 10. Acacetin-7-O-beta-D-galactopyranoside, an anti-HIV principle from Chrysanthemum morifolium and a structure-activity correlation with some related flavonoids.
AID1408300Cytotoxicity against human PWR-1E cells assessed as decrease in cell viability after 3 days by WST-1 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship and pharmacokinetic studies of 3-O-substitutedflavonols as anti-prostate cancer agents.
AID1879039Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as tetracycline MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID701064Inhibition of SYK in human mast cells assessed as reduction in mast cell degranulation2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Discovery and development of spleen tyrosine kinase (SYK) inhibitors.
AID1315575In vivo inhibition of MAOA in ICR mouse brain at 20 mg/kg administered via oral gavage using kynuramine dihydrobromide as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins in presence of MAOB inhibitor deprenyl by fl2016European journal of medicinal chemistry, Oct-04, Volume: 121Antidepressant-like effects and mechanisms of flavonoids and related analogues.
AID1879084Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of kanamycin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID444613Inhibition of Beta-lactamase AmpC by quantitative high throughput screening2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease.
AID1516853Antifungal activity against Candida albicans ATCC 10231 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1357281Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS addition and measured after 24 hrs by Griess assay2018European journal of medicinal chemistry, Jun-10, Volume: 153Anti-inflammatory effects of flavonoids in neurodegenerative disorders.
AID1264956Cytotoxicity against human MSC assessed as cell viability at 1 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264954Cytotoxicity against human MSC assessed as cell viability at 5 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID671219Inhibition of prostate specific antigen expression in human 22Rv1 cells assessed as PSA protein level at 10 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID1879043Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as ciprofloxacin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879052Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as ampicillin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1879115Binding affinity to NDM-1 (unknown origin) assessed as binding free energy by fluorescence quenching method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1127218Binding affinity DPPC multilamellar vesicles assessed as main transition temperature at 1:20 compound/lipid ratio after 2 hrs by differential scanning calorimetry method (Rvb = 41.98 degC)2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID144650In vitro cytotoxic potency against NCI-60 human tumor cell line1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Structure-activity requirements for flavone cytotoxicity and binding to tubulin.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1127214Binding affinity to 0.5 mg/ml of DPPC multilamellar vesicles at 100 uM after 2 hrs by centrifugation method2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID1705065Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoi2020European journal of medicinal chemistry, Dec-15, Volume: 208Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors.
AID1338310Antiviral activity against EV71 infected in human RD cells assessed as reduction in viral plaque formation after 1 hr by crystal violet staining method2016European journal of medicinal chemistry, Nov-29, Volume: 124Identification and biochemical characterization of DC07090 as a novel potent small molecule inhibitor against human enterovirus 71 3C protease by structure-based virtual screening.
AID74123Inhibition constant of compound against binding of Yeast Glyoxalase I1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules.
AID1879058Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as ciprofloxacin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1516852Antifungal activity against Candida albicans 53 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1879100Inhibition of metallo-beta-lactamase NDM-1 (unknown origin) using nitrocefin as substrate preincubated for 15 min followed by substrate addition and measured after 15 min by microplate reader assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID441661Stability in phosphate buffer at pH 7.4 after 90 mins by spectrophotometry2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase.
AID309800Selectivity for 12h-LO over 15-hLO2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID1879059Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as spectinomycin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID397978Cytotoxicity against mouse HT22 cells at 10 uM after 24 hrs by MTT assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity.
AID1516854Antifungal activity against Candida glabrata 507 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID596672Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 10 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1879071Synergistic antibacterial activity against pET28a NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of kanamycin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879049Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as rifampicin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879044Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as spectinomycin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1264949Cytotoxicity against human MSC assessed as decrease in cell number at 1 to 10 uM after 9 days by methylene blue staining based microscopy relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264953Cytotoxicity against human MSC assessed as cell viability at 1 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID379054Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID1264947Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 10 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID681188TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 uM, Fisetin: 50 uM) in BCRP-expressing NCI-H460 cells2004Molecular pharmacology, May, Volume: 65, Issue:5
Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
AID1879054Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as tetracycline MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID646589Neuroprotective activity against glutamate-induced GSH loss in mouse HT22 cells assessed as intracellular GSH level at 1 to 10 uM after 24 hrs2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
AID456317Antioxidant activity assessed as trolox equivalent by TEAC assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID1879090Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of spectinomycin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID429118Antagonist activity at glucocorticoid receptor in human MDA-kb2 cells assessed as inhibition of Dex-induced luciferase activity by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.
AID1572646Inhibition of human recombinant CK2 expressed in Escherichia coli using RRRADDSDDDDD as substrate after 10 mins in presence of [gamma-32P]ATP2019Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5
A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.
AID697064Inhibition of duck liver FASN2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID646592Antioxidant activity against ABTS radical assessed as trolox equivalent after 4 mins by TEAC assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
AID1879119Binding affinity to NDM-1 (unknown origin) assessed as binding constant by fluorescence quenching method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1264952Cytotoxicity against human MSC assessed as cell viability at 10 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID696769Cytotoxicity against human HepG2 cells by MTT assay2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID1631841Inhibition of human DHFR at 50 uM using folic aid as substrate by spectrophotometric analysis2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1879079Synergistic antibacterial activity against pET28a NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of doxycycline by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID378674Inhibition of thymocyte protein tyrosine kinase2006Journal of natural products, Jan, Volume: 69, Issue:1
A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets.
AID1264946Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 5 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1631839Inhibition of Leishmania mexicana DHFR at 50 uM using folic aid as substrate by spectrophotometric analysis2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1879108Inhibition of Escherichia coli BL21(DE3) (pET28a) metallo-beta-lactamase NDM-1 expression up to 32 ug/ml incubated for 6 hrs by Western blot analysis2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID397977Neuroprotective effect against iodoacetic acid-induced ischemia in mouse HT22 cells treated simultaneously with iodoacetic acid for 2 hrs followed by incubation in fresh medium containing drug alone for 20 hrs measured after 4 hrs by MTT assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity.
AID241232Inhibition of Cyclin-dependent kinase 5-p25nck5a2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.
AID298693Inhibition of CDK22007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
3-Hydroxychromones as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
AID1879061Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as streptomycin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879087Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of vancomycin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID494832Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF542010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Integrated ligand and structure based studies of flavonoids as fatty acid biosynthesis inhibitors of Plasmodium falciparum.
AID265758Inhibition of FabZ2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID1879109Inhibition of Escherichia coli ZC-YN3 metallo-beta-lactamase NDM-1 expression up to 32 ug/ml incubated for 6 hrs by Western blot analysis2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID339056Inhibition of Moloney murine leukemia virus reverse transcriptase using (riboadenylic acid)n(deoxythymidylic acid)12-18 as template primer by liquid scintillation counting1992Journal of natural products, Feb, Volume: 55, Issue:2
Inhibitory effects of flavonoids on Moloney murine leukemia virus reverse transcriptase activity.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1879034Synergistic antibacterial activity against pET28a NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of meropenem by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID397983Inhibition of p38 MAPK activation in mouse HT22 cells assessed as MAPKAPK2 phosphorylation at 10 uM treated simultaneously with iodoacetic acid for 2 hrs followed by 2 hrs of recovery in presence of drug alone by immunoblot analysis2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity.
AID1127224Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID397984Inhibition of JNK activation in mouse HT22 cells assessed as c-jun phosphorylation at 10 uM treated simultaneously with iodoacetic acid for 2 hrs followed by 2 hrs of recovery in presence of drug alone by immunoblot analysis2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity.
AID1879045Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as lincomycin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1127222Binding affinity DPPC multilamellar vesicles assessed as chemical shift at 1:5 compound/lipid ratio at 303 K by nuclear magnetic resonance analysis2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID1247842Inhibition of recombinant human CK2 expressed in Escherichia coli using RRRADDSDDDDD as substrate after 10 mins2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Structural Insight into the Interactions between Death-Associated Protein Kinase 1 and Natural Flavonoids.
AID1879106Bactericidal activity against pET28a-NDM-1 producing Escherichia coli BL21(DE3) at 32 ug/ml measured within 3 hrs in presence of meropenem by time kill curve assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879118Binding affinity to NDM-1 H250A mutant (unknown origin) assessed as binding free energy by fluorescence quenching method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID338026Inhibition of rat liver mitochondrial ATPase assessed as specific activity at 0.42 mM relative to control
AID1879056Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as vancomycin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID441664Cytotoxicity against human HepG2 cells upto 200 umol/L after 24 hrs by MTS assay2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase.
AID1127220Binding affinity DPPC multilamellar vesicles assessed as main transition temperature at 1:2 compound/lipid ratio after 2 hrs by differential scanning calorimetry method (Rvb = 41.98 degC)2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID257079Inhibitory activity against PIM1 at 1 uM2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
AID332651Inhibition of calf thymus DNA topoisomerase 1 catalytic domain-mediated supercoiled Escherichia coli pUC8 DNA relaxation after 30 mins by agarose gel electrophoresis1995Journal of natural products, Feb, Volume: 58, Issue:2
Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships.
AID1744553Permeability constant, logPe of compound incubated for 2 to 30 hrs by PAMPA assay2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID1127227Antiproliferative activity against human MCF7 cells assessed as cell growth at 10'-4 ug/ml after 48 hrs by SRB assay relative to control2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID1879114Inhibition of class D metallo-beta-lactamase OXA-48 (unknown origin) up to 64 ug/ml using nitrocefin as substrate preincubated for 15 min followed by substrate addition and measured after 15 min by microplate reader assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1127217Binding affinity DPPC multilamellar vesicles assessed as pre-transition temperature at 1:10 compound/lipid ratio after 2 hrs by differential scanning calorimetry method (Rvb = 34.10 degC)2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID671217Inhibition of androgen receptor expression in human 22Rv1 cells assessed as AR protein level at 10 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID1264945Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 1 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID311148Inhibition of PIM1 kinase2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
AID1264951Cytotoxicity against human MSC assessed as cell viability at 5 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID310882Inhibition of HIV1 replication2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Simple criterion for selection of flavonoid compounds with anti-HIV activity.
AID1516897Antifungal activity against Trichophyton rubrum after 5 days2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID332652Inhibition of human DNA topoisomerase 2 catalytic domain-mediated knotted bacteriophage P4Virl dell0 DNA unknotting by agarose gel electrophoresis1995Journal of natural products, Feb, Volume: 58, Issue:2
Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships.
AID1127221Binding affinity DPPC multilamellar vesicles assessed as chemical shift at 1:5 compound/lipid ratio at 323 K by nuclear magnetic resonance analysis2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID1879038Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as kanamycin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1832961Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced TNF-alpha secretion at 10 uM incubated for 2 followed by LPS stimulation and measured after 22 hrs by ELISA relative to control2021Bioorganic & medicinal chemistry, 11-01, Volume: 49Design, synthesis and bioactivity evaluation of fisetin derivatives as potential anti-inflammatory agents against LPS-induced acute lung injury.
AID1879102Inhibition of class A metallo-beta-lactamase KPC-2 (unknown origin) using nitrocefin as substrate preincubated for 15 min followed by substrate addition and measured after 15 min by microplate reader assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879080Synergistic antibacterial activity against pET28a NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of rifampicin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID404069In vivo antitumor activity against mouse L1210 cells
AID1879120Binding affinity to NDM-1 V73A mutant (unknown origin) assessed as binding constant by fluorescence quenching method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879055Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as florfenicol MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879075Synergistic antibacterial activity against pET28a NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of cefotaxime by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1462059Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1879078Synergistic antibacterial activity against pET28a NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of imipenem by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1516847Antifungal activity against Candida parapsilosis 96 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1832967Anti-inflammatory activity against C57BL/6 mouse model of LPS-induced acute lung injury assessed as reduction in cell count in broncho alveolar lavage fluid at 20 mg/kg, IG treated 0.5 hrs before LPS stimulation by ELISA2021Bioorganic & medicinal chemistry, 11-01, Volume: 49Design, synthesis and bioactivity evaluation of fisetin derivatives as potential anti-inflammatory agents against LPS-induced acute lung injury.
AID338029Inhibition of beef heart mitochondrial NADH oxidase assessed as complete enzyme inhibition at 100 nmol/mg
AID1879041Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as vancomycin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879086Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of florfenicol by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID646588Neuroprotective activity in mouse HT22 cells assessed as reduction in IAA-induced ischemia after 24 hrs by MTT assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
AID1516859Antifungal activity against Candida glabrata 482 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID502292Antioxidant activity assessed as DDPH radical scavenging activity2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Relationships between structures of hydroxyflavones and their antioxidative effects.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1127219Binding affinity DPPC multilamellar vesicles assessed as main transition temperature at 1:5 compound/lipid ratio after 2 hrs by differential scanning calorimetry method (Rvb = 41.98 degC)2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID397979Effect on intracellular ATP level in mouse HT22 cells by chemiluminescent assay in presence of iodoacetic acid2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity.
AID441660Inhibition of human recombinant AChE by Ellman's method2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase.
AID1462061Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1639204Antioxidant activity assessed as galvinoxyl radical scavenging activity by measuring second order rate constant by UV-vis spectrometric analysis2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and radical-scavenging activity of C-methylated fisetin analogues.
AID1127226Antiproliferative activity against human HepG2 cells assessed as cell growth at 10'-4 ug/ml after 48 hrs by SRB assay relative to control2014European journal of medicinal chemistry, May-22, Volume: 79In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane.
AID1879060Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as lincomycin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID338750Inhibition of bovine thymus p56LCK-catalyzed phosphorylation of angiotensin 1 by SDS-PAGE
AID444615Inhibition of Trypanosoma cruzi cruzain by Flexstation microplate spectrofluorimetry2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease.
AID1879083Synergistic antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of ampicillin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1264955Cytotoxicity against human MSC assessed as cell viability at 10 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1247840Displacement of ANS from DAPK1 catalytic domain (1 to 285) (unknown origin) after 30 mins by fluorescence assay2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Structural Insight into the Interactions between Death-Associated Protein Kinase 1 and Natural Flavonoids.
AID357254Antifungal activity against Candida albicans ATCC 900282002Journal of natural products, Dec, Volume: 65, Issue:12
Fatty acid synthase inhibitors from plants: isolation, structure elucidation, and SAR studies.
AID1879076Synergistic antibacterial activity against pET28a NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of ciprofloxacin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1408299Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 3 days by WST-1 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Structure-activity relationship and pharmacokinetic studies of 3-O-substitutedflavonols as anti-prostate cancer agents.
AID1462060Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
3-O-Substituted-3',4',5'-trimethoxyflavonols: Synthesis and cell-based evaluation as anti-prostate cancer agents.
AID1879107Synergistic antibacterial activity against pET28a-NDM-1 producing Escherichia coli BL21(DE3) assessed as zone of inhibition up to 64 ug/ml incubated for 24 hrs in presence of meropenem2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID354858Inhibition of DNA topoisomerase 11996Journal of natural products, Jul, Volume: 59, Issue:7
DNA topoisomerase I inhibitors: cytotoxic flavones from Lethedon tannaensis.
AID354859Inhibition of DNA topoisomerase 21996Journal of natural products, Jul, Volume: 59, Issue:7
DNA topoisomerase I inhibitors: cytotoxic flavones from Lethedon tannaensis.
AID1744554Octanol-water distribution coefficient, log D of the compound at pH 7.4 after 1 hr by UV-VIS spectroscopic analysis2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID646590Neurotrophic activity in rat PC12 cells assessed as neurite outgrowth at 1 to 10 uM after 24 hrs2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
AID265759Inhibition of FabI2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID1879101Inhibition of metallo-beta-lactamase VIM-1 (unknown origin) using nitrocefin as substrate preincubated for 15 min followed by substrate addition and measured after 15 min by microplate reader assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879040Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as florfenicol MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID399340Inhibition of xanthine oxidase assessed as decrease in uric acid production by spectrophotometry1998Journal of natural products, Jan, Volume: 61, Issue:1
Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers.
AID1264958Cytotoxicity against human MSC assessed as cell viability at 10 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1879074Synergistic antibacterial activity against pET28a NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of vancomycin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1516848Antifungal activity against Candida tropicalis 166 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID671218Inhibition of androgen receptor expression in human 22Rv1 cells assessed as AR protein level at 20 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID378676Inhibition of CK22006Journal of natural products, Jan, Volume: 69, Issue:1
A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets.
AID241206Inhibition of cyclin-dependent kinase 1/cyclinB2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.
AID1516846Antifungal activity against Cryptococcus neoformans after 72 hrs2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID93507IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavage1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study.
AID646594Neuroprotective activity in New Zealand white rabbit small clot embolism model assessed as reduction in stroke-induced behavioural deficits at 50 mg/kg, iv administered 5 mins post-embolization measured after 24 hrs2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
AID1879117Binding affinity to NDM-1 M248A mutant (unknown origin) assessed as binding free energy by fluorescence quenching method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879077Synergistic antibacterial activity against pET28a NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of spectinomycin by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID494830Inhibition of Plasmodium falciparum FabI2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Integrated ligand and structure based studies of flavonoids as fatty acid biosynthesis inhibitors of Plasmodium falciparum.
AID242481Inhibition of human cyclin-dependent kinase 6 complex with a virus-encoded cyclin from herpesvirus saimiri (Vcyclin)2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.
AID378677Inhibition of PI3K2006Journal of natural products, Jan, Volume: 69, Issue:1
A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets.
AID1879072Synergistic antibacterial activity against pET28a NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as fractional Inhibitory concentration index incubated for 18 to 24 hrs in presence of tetracycline by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1879050Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as colistin MIC incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID654747Inhibition of GST-tagged Human papillomavirus 16 protein E6 interaction with His-tagged human caspase 8 expressed in Escherichia coli at 20 nM to 20 uM after 1 hr incubation followed by overnight incubation by Alpha screening technique2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Small molecule inhibitors of the HPV16-E6 interaction with caspase 8.
AID441665Cytotoxicity against human A549 cells upto 200 umol/L after 24 hrs by MTS assay2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase.
AID779050Inhibition of CK2 (unknown origin)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Discovery and characterization of synthetic 4'-hydroxyflavones-New CK2 inhibitors from flavone family.
AID1879122Binding affinity to NDM-1 H250A mutant (unknown origin) assessed as binding constant by fluorescence quenching method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1811Experimentally measured binding affinity data derived from PDB2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.
AID1799665Inhibition Assay from Article 10.1080/14756360109162353: \\Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer.\\2001Journal of enzyme inhibition, Jan, Volume: 16, Issue:1
Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer.
AID1799639Kinase Assay from Article 10.1002/cbic.201000487: \\Biological evaluation and structural determinants of p38u00CEu00B1 mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.\\2010Chembiochem : a European journal of chemical biology, Dec-10, Volume: 11, Issue:18
Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
AID1801043DXR Inhibition Assay from Article 10.1016/j.bioorg.2015.02.008: \\Flavonoids: true or promiscuous inhibitors of enzyme? The case of deoxyxylulose phosphate reductoisomerase.\\2015Bioorganic chemistry, Apr, Volume: 59Flavonoids: true or promiscuous inhibitors of enzyme? The case of deoxyxylulose phosphate reductoisomerase.
AID1796044Kinase Inhibition Assay from Article 10.1021/jm049353p: \\Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.\\2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.
AID1802643DPP III Enzyme Activity Assay from Article 10.1111/cbdd.12887: \\Validation of flavonoids as potential dipeptidyl peptidase III inhibitors: Experimental and computational approach.\\2017Chemical biology & drug design, 04, Volume: 89, Issue:4
Validation of flavonoids as potential dipeptidyl peptidase III inhibitors: Experimental and computational approach.
AID1798320In Vitro alpha-Amylase Activity Assay from Article 10.1021/jm800115x: \\Flavonoids for controlling starch digestion: structural requirements for inhibiting human alpha-amylase.\\2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Flavonoids for controlling starch digestion: structural requirements for inhibiting human alpha-amylase.
AID1801097Aurora B Kinase Assay from Article 10.1111/cbdd.12445: \\Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.\\2015Chemical biology & drug design, May, Volume: 85, Issue:5
Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.
AID1798717Solid-Phase ELISA Kinase Assay from Article 10.1158/1535-7163.MCT-06-0397: \\Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.\\2007Molecular cancer therapeutics, Jan, Volume: 6, Issue:1
Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (648)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (1.39)18.7374
1990's21 (3.24)18.2507
2000's88 (13.58)29.6817
2010's366 (56.48)24.3611
2020's164 (25.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.06 (24.57)
Research Supply Index6.51 (2.92)
Research Growth Index5.46 (4.65)
Search Engine Demand Index149.57 (26.88)
Search Engine Supply Index3.98 (0.95)

This Compound (47.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.60%)5.53%
Reviews47 (7.05%)6.00%
Case Studies1 (0.15%)4.05%
Observational0 (0.00%)0.25%
Other615 (92.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]